| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 2 topline data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
SELLAS Life Sciences Group, Inc.$12.76
-0.73 (-5.4%)
C 47Pipeline Score Overvalued Pharma · Commercial
Market Cap
1.45 B
EPS
-0.23
P/E Ratio
-
Value Trade
61.25 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
5.13 M
Operating CF
-8.85 M
Total Assets
114.18 M
Total Liabilities
6.76 M
Equity
107.41 M
D/E Ratio
12,345
8.66 %
Week
54.67 %
1 Month
94.5 %
3 Month
415.23 %
6 Month
-18.62 %
5 Year
-100 %
All Time
Cash Data
Cash Position
107.10 M
Monthly Burn
2.95 M
Runway
34.6 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
6.41 M
52 Week Range
1.39 - 9.10
% held by Insiders
1.21 %
% held by Institutions
29.21 %
Enterprise Value
1.34 B
Total Shares
186.01 M
Short %
34.48 %
Float Shares
183.60 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for SELLAS Life Sciences Group, Inc.
874Total events
3Upcoming
192Tier-1 (high impact)
2011 – 2026Coverage
Upcoming catalysts 3
Event history 871
May 27, 2026
◆Oral PresentationPresentation
TD Cowen’s 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
May 11, 2026
◆Enrollment UpdateGalinpepimut-STrial
78 events occurred in REGAL trial as of May 11, 2026
Acute Myeloid Leukemiasource ↗
May 11, 2026
◆Enrollment MilestoneGalinpepimut-STrial
78 events occurred in REGAL trial as of May 11, 2026
Acute Myeloid Leukemia (AML)source ↗
May 11, 2026
▲First Patient DosedSLS009Trial
First patient dosed in Phase 2 trial of SLS009 in newly diagnosed first-line AML
Acute Myeloid Leukemia (AML)source ↗
Apr 21, 2026
◆Poster PresentationSLS009Presentation
Poster presentation of preclinical data on SLS009 in AML at AACR 2026
acute myeloid leukemia (AML)source ↗
Q2 2026
◆Trial InitiationSLS009Trial
Enrollment initiation at European sites for SLS009 in combination with AZA/VEN in frontline AML
newly diagnosed AML with high-risk featuressource ↗
Q2 2026
●Enrollment MilestoneSLS009Trial
Enrollment of approximately 40 patients in Europe anticipated in Q2 2026
newly diagnosed AMLsource ↗
Drug Pipeline Intelligence
C47
Pipeline Score $558M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.4x
rNPV / MCap Top 69%
Micro Cap (rank 283 of 911)
Percentile RankSELLAS Life Sciences Group, Inc. carries a moderate pipeline score (47/100), with $1.4B risk-adjusted pipeline value, led by Galinpepimut-S in Multiple Myeloma (Phase 1), across $55B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Galinpepimut-S Monoclonal antibody | Acute Myeloid Leukemia | Phase 3 | NCT04229979 | 65% | $689M | ACTIVE NOT_RECRUITING | 149 | SLOW | C (58) | Dec 1, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Galinpepimut-S Rare Pediatric | Acute Myeloid Leukemia | Phase 3 | 2026-05-13 | 78 events recorded so far | SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More | |
Galinpepimut-S Rare Pediatric | Acute Myeloid Leukemia | Phase 3 | 2026-05-13 | 78 events recorded so far | SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More | |
Galinpepimut-S Rare Pediatric | Acute Myeloid Leukemia | Phase 3 | 2026-05-13 | 78 events recorded so far | SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SLS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SLS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SLS▲ +13.6%on this news
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
SELLAS Life Sciences Group, Inc. has announced participation in several upcoming investor conferences, including the Stifel Virtual Targeted Oncology Forum and A.G.P.'s Annual Virtual Healthcare Conference. CEO Angelos Stergiou will represent the company at these events, highlighting SELLAS's focus on developing novel cancer therapies, including their lead product GPS and the small molecule CDK9 inhibitor SLS009.
Read more →SLS▲ +25.1%on this news· ran to +42% by day 1shared move
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
SELLAS Life Sciences reported its Q1 2026 financial results, highlighting the ongoing Phase 3 REGAL trial of Galinpepimut-S (GPS) in AML, with 78 events recorded so far. The company is also advancing its Phase 2 trial of SLS009, targeting high-risk AML patients. Despite a net loss increase, SELLAS maintains a strong cash position of $107.1 million.
Read more →SLSSELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update - Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
SELLAS Life Sciences reported its financial results for Q1 2026 while providing updates on its key clinical trials. As of May 11, 2026, the pivotal Phase 3 REGAL trial of Galinpepimut-S (GPS) has recorded 78 events, with the final analysis pending on the 80th event. In addition, the company is advancing with its Phase 2 trial of SLS009, targeting newly diagnosed AML patients, and has shown positive preclinical data. SELLAS holds a strong cash position of $107.1 million, signaling good financial health despite an increased net loss compared to the previous year.
Read more →SLS▼ -8.5%on this news
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences reported its financial results for 2025, highlighting significant advancements in its clinical programs for acute myeloid leukemia (AML). The company is nearing the final analysis of its Phase 3 REGAL trial for GPS and has initiated a Phase 2 trial for SLS009. With a strong cash position and positive trial results, SELLAS aims to expand its treatment options in AML. However, it also faces challenges, including a reported net loss and the uncertainty of trial outcomes.
Read more →SLS▼ -6%on this newsshared move
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
SELLAS Life Sciences announced that preclinical data for its CDK9 inhibitor SLS009 will be presented at the AACR conference in April 2026. The data show that SLS009 significantly increases apoptosis in acute myeloid leukemia (AML) cells and is especially effective against mutations that typically indicate poor prognosis. Initial results suggest that the drug may be a powerful treatment option across different genetic backgrounds of AML. The presentation will take place on April 21, 2026, and aims to highlight the clinical potential of SLS009.
Read more →SLS▼ -8.2%on this newsshared move
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
SELLAS Life Sciences has enrolled the first patient in its Phase 2 trial for SLS009, a CDK9 inhibitor targeting newly diagnosed acute myeloid leukemia (AML) patients. The study aims to enroll 80 patients, focusing on those unlikely to benefit from standard therapies. Topline data is expected by Q4 2026, following promising results in relapsed/refractory AML.
Read more →SLS▼ -6.6%on this news
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
SELLAS Life Sciences has partnered with IMPACT-AML to advance the SLS009 clinical program in Europe. This collaboration will facilitate a clinical study evaluating SLS009, a CDK9 inhibitor, across multiple European sites. The study aims to enroll around 40 patients with newly diagnosed AML, enhancing patient access and participation in the clinical program.
Read more →SLS▲ +16.7%on this news· ran to +52% by day 3
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
SELLAS Life Sciences provided an update on its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukemia (AML). The trial continues following a recommendation from the Independent Data Monitoring Committee, with 72 of the required 80 events reported. The company remains blinded to efficacy data and will announce the final analysis upon reaching the event threshold.
Read more →SLSSELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
SELLAS Life Sciences presented positive Phase 2 data for SLS009, a CDK9 inhibitor, in combination with azacitidine and venetoclax for relapsed/refractory acute myeloid leukemia with myelodysplastic syndrome-related changes. The study showed a 46% overall response rate among 35 evaluable patients, with median overall survival exceeding expectations. The combination was well tolerated with no dose-limiting toxicities.
Read more →SLSSELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences reported its Q3 2025 financial results, highlighting positive developments in its AML-focused pipeline. The Phase 2 data for SLS009 has been accepted for presentation at the ASH Annual Meeting, and plans for a new trial in first-line AML patients are underway. The company has a solid cash position following recent warrant exercises, positioning it for growth.
Read more →SLSSELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting
SELLAS Life Sciences announced that data from its Phase 2 study of SLS009 will be presented at the 2025 ASH Annual Meeting. The study evaluates SLS009, a CDK9 inhibitor, in combination with azacitidine and venetoclax for patients with relapsed/refractory AML. The presentation aims to showcase the potential of SLS009 in addressing difficult-to-treat cancers.
Read more →SLSSELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds
SELLAS Life Sciences Group announced the exercise of existing warrants, generating approximately $31 million in gross proceeds. The investor will receive new warrants for the same number of shares at an exercise price of $2.00. The transaction is expected to close on October 28, 2025. Additionally, SELLAS will host a virtual R&D Day to discuss acute myeloid leukemia treatment advancements.
Read more →SLSSELLAS Life Sciences to Participate in the J.P. Morgan U.S. Opportunities Forum
SELLAS Life Sciences Group, Inc. announced that its CEO, Dr. Angelos Stergiou, will participate in the J.P. Morgan U.S. Opportunities Forum on November 12, 2025. The event will take place at the Kimpton EPIC Hotel in Miami, Florida, and will feature one-on-one investor meetings. SELLAS is advancing its lead product candidate, GPS, and developing SLS009, a CDK9 inhibitor.
Read more →SLSSELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
SELLAS Life Sciences announced that preclinical data for SLS009, a CDK9 inhibitor, will be presented at the ESMO Congress 2025. The study shows that SLS009, both alone and in combination with venetoclax, significantly prolongs survival in T-cell prolymphocytic leukemia compared to venetoclax alone. The findings suggest SLS009 could be a critical treatment option for this aggressive leukemia.
Read more →SLSSELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
SELLAS Life Sciences Group will host a virtual R&D Day on October 29, 2025, to discuss advancements in acute myeloid leukemia (AML) therapies. The event will feature insights on the ongoing Phase 3 REGAL trial of Galinpepimut-S (GPS) and updates on the SLS009 program. Key opinion leaders will address the unmet needs in AML treatment and present recent Phase 2 data for SLS009.
Read more →SLSSELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
SELLAS Life Sciences Group has announced the immediate exercise of warrants by a current institutional investor, which will result in approximately $23.6 million in gross proceeds. This exercise involves the issuance of new warrants that can be exercised immediately and have a five-and-a-half-year term. The transaction is set to close on or about September 12, 2025, pending customary closing conditions. SELLAS focuses on developing novel therapies for various cancer indications, including its lead candidate GPS and SLS009, a differentiated CDK9 inhibitor.
Read more →SLSSELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Positive IDMC Recommendation to Continue Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Without Modification
SELLAS Life Sciences Group reported its second quarter 2025 financial results, highlighting positive developments in its AML pipeline, particularly for SLS009. The IDMC provided a favorable recommendation to continue the Phase 3 REGAL trial of GPS without modifications. Phase 2 results for SLS009 showed a 44% response rate among patients, which outperformed historical benchmarks. The Company expects to commence enrollment for an additional trial in Q1 2026, maintaining a strong cash position and recent strategic expansions.
Read more →SLSSELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
SELLAS Life Sciences announced that the Independent Data Monitoring Committee has positively reviewed the Phase 3 REGAL trial of GPS in acute myeloid leukemia, recommending its continuation without modifications. The trial aims to evaluate the overall survival of patients who achieved complete remission after second-line salvage therapy. The next analysis will occur after 80 events, with final results expected by year-end.
Read more →SLSSELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study
SELLAS Life Sciences announced that its Phase 2 trial of SLS009 in relapsed/refractory acute myeloid leukemia met all primary endpoints, showing strong efficacy and safety. The trial results indicate a significant potential for SLS009 to improve outcomes in AML patients. Following FDA guidance, the company plans to initiate a trial for newly diagnosed patients to further explore the therapy's effectiveness.
Read more →SLSSELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board
SELLAS Life Sciences has appointed Dr. Linghua Wang to its Scientific Advisory Board, enhancing its expertise in cancer research. Dr. Wang is recognized for her work in cancer immunogenomics and computational biology, which aligns with SELLAS's focus on precision medicine. This appointment comes after the addition of other prominent experts, strengthening the company's scientific advisory resources. The board's collective knowledge is expected to guide SELLAS through upcoming clinical milestones.
Read more →SLSSELLAS Life Sciences to be Added to Russell 3000 and Russell 2000 Indexes
SELLAS Life Sciences Group, Inc. announced its addition to the Russell 3000 and Russell 2000 Indexes, effective after the U.S. market close on June 27, 2025. This recognition signifies an important milestone for SELLAS, marking the progress in their clinical development and positioning the firm for increased visibility with investors. Following this addition, the company aims to advance its clinical trials, including the ongoing studies of SLS009 and GPS in acute myeloid leukemia. The Company emphasizes the potential for these therapies to address various cancer indications.
Read more →SLSSELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts
SELLAS Life Sciences Group, Inc. announced the addition of two distinguished oncology experts, Philip C. Amrein, MD, and Alex Kentsis, MD, PhD, to its Scientific Advisory Board. This expansion is expected to strengthen the company's strategic guidance as it progresses through significant clinical milestones, including topline Phase 2 data for SLS009 and final analysis of the REGAL trial. The expertise of the new advisory members will be crucial for the development of SELLAS’ therapeutic pipeline focused on cancer indications.
Read more →SLS▼ -7.6%on this newsshared move
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
SELLAS Life Sciences presented positive preclinical data for SLS009 at the 2025 ASCO Annual Meeting, highlighting its efficacy in ASXL1 mutated colorectal cancer cell lines. The results indicated that SLS009 demonstrated a significant anti-proliferative effect, with a substantial portion of ASXL1 mutant cells showing low IC50 values. The findings suggest that SLS009 may provide a targeted treatment option with fewer side effects compared to current therapies. The presentation underscores the potential of ASXL1 as a biomarker for therapy effectiveness in these cancer cases.
Read more →SLS▲ +10.9%on this news
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase
SELLAS Life Sciences Group, Inc. announced that its CEO, Dr. Angelos Stergiou, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025. The company's focus is on developing novel therapeutics for various cancer indications, with a lead product candidate, GPS, aiming to address multiple tumor types. Additionally, SELLAS is advancing SLS009, a small molecule CDK9 inhibitor, showing promise in treating patients with unfavorable prognostic factors.
Read more →SLS▲ +6%on this news· ran to +28% by day 3shared move
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
SELLAS Life Sciences Group has announced that the first pediatric patient has been dosed in its ongoing Phase 2 trial evaluating SLS009, a CDK9 inhibitor, for relapsed/refractory acute myeloid leukemia (AML). This milestone reflects the company's commitment to addressing serious unmet medical needs in this population. The trial includes various patient cohorts and aims to identify biomarkers while targeting a response rate and median survival goals. With Rare Pediatric Disease Designation from the FDA, SELLAS hopes to leverage potential regulatory advantages in the future.
Read more →SLS▼ -8.4%on this newsshared move
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update - Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed Refract
SELLAS Life Sciences reported strong financial results for Q1 2025, including positive overall survival outcomes from its SLS009 trial in relapsed refractory acute myeloid leukemia (AML). The median overall survival for patients was greatly improved compared to historical benchmarks. The company also showcased efficacy data for SLS009 in pediatric ALL xenografts. Despite the positive developments, SELLAS reported a net loss of $5.8 million, though their financial position has been bolstered through a successful direct offering.
Read more →SLSSELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
SELLAS Life Sciences presented preclinical data at the AACR 2025 conference showing that their CDK9 inhibitor, SLS009, is effective in treating TP53 mutated Acute Myeloid Leukemia (AML). The data revealed significant reductions in leukemia cell populations and promising outcomes, adding potential new options for patients facing poor prognoses. The ongoing Phase 2 clinical trials further emphasize the drug's efficacy and safety in combination with established therapies.
Read more →SLSSELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
SELLAS Life Sciences Group, Inc. announced its participation in the 2025 American Society of Clinical Oncology Annual Meeting, where it will present findings on SLS009's efficacy in ASXL1 mutated colorectal cancer. The poster session is scheduled for June 2, 2025. SLS009 is currently undergoing evaluation in a Phase 2 clinical trial to assess its safety and effectiveness in combination with other therapies, focusing on AML patients with ASXL1 mutations. The full text of the relevant abstract will be released on May 22, 2025.
Read more →SLSSELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
SELLAS Life Sciences announced positive results from Cohort 3 of the Phase 2 trial for SLS009, a CDK9 inhibitor targeting relapsed/refractory acute myeloid leukemia (AML). The trial showed a median overall survival of 8.8 months, surpassing the historical benchmark, and a 67% overall response rate in patients with AML related to myelodysplasia. The company is awaiting full data and FDA feedback in 2025 as they continue exploring SLS009's potential through expansion cohorts.
Read more →SLSSELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Le
SELLAS Life Sciences Group, Inc. reported positive results from the interim analysis of its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukemia, showing preliminary signs of effectiveness. Additionally, promising data was shared regarding SLS009, which demonstrated a 56% overall response rate in a Phase 2 trial. The company also raised $25 million through a direct offering to strengthen its financial position. Overall, SELLAS is advancing its clinical development pipeline while achieving key regulatory designations that may expedite drug approvals.
Read more →SLSSELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
SELLAS Life Sciences has announced promising data from a Phase 2a trial of its CDK9 inhibitor SLS009, combined with the BTK inhibitor zanubrutinib, for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The combination achieved a 67% overall response rate, which is significantly higher than the expected response for zanubrutinib alone. Six out of nine patients were still alive as of the latest follow-up, indicating a potentially important clinical benefit. Additionally, the study highlighted the potential synergy between SLS009 and zanubrutinib, paving the way for future treatment options in DLBCL.
Read more →SLS▼ -17%on this news
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SELLAS Life Sciences Group announced a $25 million registered direct offering priced at-the-market under Nasdaq rules, involving the sale of nearly 19.7 million shares and accompanying warrants. The offering aims to raise capital for working purposes and potential future acquisitions. The deal is expected to close around January 29, 2025, contingent on customary closing conditions. This offering highlights investor interest in SELLAS amidst its ongoing development of cancer therapies, including GPS and SLS009.
Read more →SLS▼ -13.3%on this newsshared move
SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia 2025-01-23 - REGAL Successfully Passes Event-Driven (60 Deaths) Interim Analysis fo
SELLAS Life Sciences announced a positive interim analysis outcome for its Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). The Independent Data Monitoring Committee (IDMC) reviewed unblinded data and recommended that the trial continue without modifications. The analysis confirmed GPS's efficacy, indicating a median survival of over 13.5 months, which is considerably better than conventional therapies. The next evaluation will occur once a total of 80 events are reached, paving the way for the potential approval of GPS as a treatment option for AML patients.
Read more →SLS▼ -9.5%on this news
SELLAS Announces Key Business Objectives for 2025
SELLAS Life Sciences Group, Inc. has outlined significant objectives for 2025, emphasizing its focus on advancing clinical trials for its novel therapeutic candidates, particularly SLS009 for acute myeloid leukemia (AML). The company expects to release full topline Phase 2 data and receive FDA feedback, which are critical steps in its development pipeline. Additionally, an interim analysis of the Phase 3 REGAL study is scheduled for January 2025, which could significantly impact the trial's future direction. Regulatory approvals have also been granted, recognizing the potential for their therapies to address unmet medical needs in hematologic malignancies.
Read more →SLSSELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET
SELLAS Life Sciences Group, Inc. will hold a corporate update call on January 8, 2025, featuring CEO Angelos Stergiou and Dr. Yair Levy from Baylor University. They will discuss the company's prospects for the upcoming year, including updates on their lead product candidate, GPS, and the development of the small molecule CDK9 inhibitor, SLS009. This call signifies SELLAS's commitment to communication with stakeholders as it navigates through its late-stage development in cancer therapies.
Read more →SLSSELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis - - REGAL Independent D
SELLAS Life Sciences Group has announced the initiation of an interim analysis in its Phase 3 REGAL trial for the drug galinpepimut-S (GPS) in acute myeloid leukemia, following the achievement of a pre-specified milestone of 60 death events. The analysis will be conducted by the Independent Data Monitoring Committee (IDMC), which will assess the efficacy, safety, and potential futility of the treatment. CEO Angelos Stergiou emphasized the significance of this milestone and the company's commitment to develop novel therapies for cancer. Results from the interim analysis are expected to be discussed in a scheduled meeting in January 2025.
Read more →SLSSELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML
SELLAS Life Sciences announced positive data from its Phase 2 trial of SLS009, a CDK9 inhibitor, in patients with relapsed/refractory acute myeloid leukemia (r/r AML). The latest results show that the median overall survival has reached over 7.7 months, which is significantly above the historical benchmark of 2.5 months. Additionally, the trial recorded an overall response rate of 56% in patients with acute myeloid leukemia with myelodysplasia-related changes, exceeding expectations. The treatment was well-tolerated, reinforcing its potential as a new therapeutic option for this challenging patient population.
Read more →SLSSELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
SELLAS Life Sciences announced promising preclinical results indicating that ASXL1 mutations predict a favorable response to SLS009 in solid tumors. The data showed that 67% of ASXL1 mutated solid cancer cell lines demonstrated high efficacy with SLS009, contrasting with a 0% response rate in non-mutated lines. Further studies confirmed ASXL1 mutations' prevalence in colorectal and lung cancer cell lines. These findings, complemented by previous clinical data on acute myeloid leukemia, support the targeted development of SLS009 in solid tumor therapies.
Read more →SLS▼ -5.9%on this news
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Rema
SELLAS Life Sciences recently reported its financial results for Q3 2024, highlighting progress in several clinical studies, particularly the Phase 3 REGAL study of GPS in AML, which is set for interim analysis in Q4 2024. The company will present Phase 2a data for its SLS009 treatment at the ASH Annual Meeting in December. Furthermore, GPS has received FDA's Rare Pediatric Disease Designation for pediatric AML. Despite a reported net loss, the firm expects to advance further studies with promising therapies in the near future.
Read more →SLSSELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024
SELLAS Life Sciences Group, Inc. announced that it will present data from its Phase 2a trial of SLS009 at the upcoming 66th American Society of Hematology Annual Meeting. The trial demonstrated a 50% response rate for SLS009, a CDK9 inhibitor, in patients with relapsed/refractory acute myeloid leukemia after prior venetoclax treatment. Notably, the treatment improved median overall survival to 5.5 months compared to less than 2.5 months with standard therapies. The presentation will take place in San Diego on December 8, 2024, showcasing promising outcomes for challenging cancer cases.
Read more →SLSSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences announced that its immunotherapeutic candidate Galinpepimut-S (GPS) has been granted Rare Pediatric Disease Designation by the FDA for treating pediatric acute myeloid leukemia (AML). This designation may facilitate the acquisition of a Priority Review Voucher, which can be deferred or sold, potentially valued at around $100 million. GPS has exhibited positive outcomes in adult patients, particularly among younger demographics, encouraging its evaluation for pediatric applications. However, pediatric AML continues to present significant treatment challenges with high relapse rates and poor prognosis for patients.
Read more →SLSSELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
SELLAS Life Sciences Group, Inc. will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on October 15, 2024. Dr. Angelos Stergiou, the company's CEO, will represent SELLAS in this event, which aims to enhance investor engagement and provide insights into the company's developments. The focus of SELLAS is on advancing novel therapies for cancer, particularly its lead candidate GPS and the differentiated small molecule SLS009. The summit will be hosted on the M-Vest platform with registration available for investors.
Read more →SLSSELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients w
SELLAS Life Sciences reported its second quarter 2024 financial results, highlighting significant progress in its clinical trials, particularly with SLS009 in treating Acute Myeloid Leukemia (AML). The Independent Data Monitoring Committee supported the continuation of the Phase 3 REGAL study of galinpepimut-S without modifications. Preliminary data from the Phase 2a trial of SLS009 showed an overall response rate exceeding targets. Additionally, the company raised $21 million in gross proceeds to bolster its financial standing, while facing a net loss of $7.5 million.
Read more →SLSSELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
SELLAS Life Sciences Group has received Orphan Drug Designation from the European Medicines Agency for its CDK9 inhibitor, SLS009, which is aimed at treating relapsed/refractory peripheral T-cell lymphomas. This designation follows similar recognitions from the FDA, underscoring the urgency for new treatments in the aggressive PTCL patient population. Clinical trials have shown promising efficacy, with a notable response rate of 36.4% in PTCL patients. Despite these advancements, there are inherent risks associated with oncology product development and uncertainties regarding regulatory approvals.
Read more →SLS▼ -7.2%on this news
SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market
SELLAS Life Sciences announced a registered direct offering of $21 million, involving 15,849,056 shares priced at $1.325 each, which is above current market value. The offering is expected to close around August 1, 2024, pending customary closing conditions. This capital will aid in advancing their late-stage clinical programs in oncology, including treatments targeting various cancer indications. The offering has been arranged by Group LLC, acting as the sole placement agent.
Read more →SLSSELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences has been granted Rare Pediatric Disease Designation (RPDD) by the U.S. FDA for its drug SLS009, aimed at treating pediatric acute myeloid leukemia (AML). This designation allows opportunity for prioritization in the review process upon eventual market approval. SLS009's admission highlights the urgency of addressing the treatment gap for children with AML, especially those with challenging mutations. Enrollment for the ongoing Phase 2 clinical trial targeting pediatric AML patients has begun, signaling a commitment to advancing pediatric oncology treatment options.
Read more →SLSSELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia
SELLAS Life Sciences Group has announced that it received Orphan Drug Designation from the European Medicines Agency for its novel CDK9 inhibitor, SLS009, targeting acute myeloid leukemia. This designation is based on favorable data from ongoing clinical trials and follows a previous Orphan Drug Designation granted by the FDA. The company plans to advance SLS009's development in collaboration with European and U.S. regulatory bodies. They expect to release additional data regarding SLS009 in the third quarter of 2024.
Read more →SLSSELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia
SELLAS Life Sciences Group, Inc. announced that its drug SLS009 has received Rare Pediatric Disease Designation from the FDA for the treatment of pediatric acute lymphoblastic leukemia (ALL). This designation allows the company to expedite the drug's clinical development and makes it eligible for a Priority Review Voucher upon marketing approval. SLS009 has shown a favorable safety profile in trials, crucial for addressing the serious condition prevalent among children. However, challenges remain, including the uncertainty in obtaining regulatory approval and the ongoing high relapse rates associated with pediatric ALL.
Read more →SLS▼ -16.7%on this news· ran to -29% by day 1
SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia
SELLAS Life Sciences Group announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) regarding its ongoing Phase 3 REGAL clinical trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML). The IDMC found no safety or efficacy concerns and confirmed the trial could proceed without modifications. The interim analysis is anticipated to occur by the fourth quarter of 2024, adding to optimism regarding the treatment's development. Experts believe GPS may have potential applications beyond its current focus.
Read more →SLSSELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML
SELLAS Life Sciences Group has successfully completed enrollment in its Phase 2a trial of SLS009 for relapsed/refractory acute myeloid leukemia (r/r AML), achieving initial promising data. The trial saw high overall response rates of 33% and 50% in different dosing cohorts, with the 45 mg dose achieving a median overall survival of 5.4 months versus 2.5 months for standard therapy. There was strong efficacy noted, particularly in patients with ASXL1 mutations, where a 100% overall response rate was recorded. The trial continues with expansion cohorts to further investigate the efficacy of SLS009.
Read more →SLSSELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update - Announced Independent Data Monitoring Committee's (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients wi
SELLAS Life Sciences Group, Inc. reported its financial results for Q1 2024, highlighting a positive outlook from recent clinical trials. The Independent Data Monitoring Committee recommended that the Phase 3 REGAL study in Acute Myeloid Leukemia continue without modifications. Early data from the Phase 2 trial of SLS009 showed promising response rates, particularly in patients with ASXL1 mutations. Despite a net loss of $9.6 million, the company noted improvements in operational expenses and a strengthened financial position.
Read more →SLSSELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
SELLAS Life Sciences has announced encouraging preliminary data from its Phase 2 trial of SLS009, a CDK9 inhibitor targeting relapsed/refractory acute myeloid leukemia (AML) in patients with ASXL1 mutations. The results demonstrate a remarkable 100% response rate in this specific patient cohort at the optimal dosing level. The study is still ongoing, and SELLAS plans to discuss accelerated approval pathways with the FDA based on these promising findings. This research could potentially expand treatment options for AML patients, who currently have limited targeted therapies available.
Read more →SLS▼ -17.1%on this newsshared move
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
SELLAS Life Sciences announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue the Phase 3 REGAL clinical trial of its drug galinpepimut-S (GPS) for acute myeloid leukemia. The IDMC's review showed no safety concerns, and the trial has successfully completed patient enrollment. A subsequent efficacy and safety assessment is planned for June 2024. The study aims to evaluate overall survival in patients who achieved complete remission after salvage therapy.
Read more →SLSSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update - Announced Phase 2a study of SLS009 in r r AML Showing 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeding th
SELLAS Life Sciences reported positive financial results and corporate updates for 2023, highlighted by a 50% response rate in its Phase 2a study of SLS009 for relapsed refractory acute myeloid leukemia (AML). The company completed enrollment in the Phase 3 REGAL study and received FDA Fast Track Designation for SLS009. Expectations are set for further data releases from ongoing studies throughout 2024. The company appears well-positioned for continued advancement in its clinical pipeline.
Read more →SLSSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
SELLAS Life Sciences has announced positive topline data from the Phase 2a study of SLS009 in patients with relapsed/refractory acute myeloid leukemia (r/r AML), showing a 50% response rate that surpasses the initial target. Additionally, the Steering Committee provided an update on the Phase 3 REGAL study, indicating that enrollment has been completed and an interim analysis is expected soon. The results underscore SLS009's promising potential, particularly in patients with specific biomarkers, although some concerns remain regarding the discontinuation of treatment among patients.
Read more →SLSSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SELLAS Life Sciences Group announced the completion of a $20 million registered direct offering of shares and warrants. The offering involved the issuance of 13,029,316 shares at a price of $1.535 per share, alongside warrants with an exercise price of $1.41 per share. The net proceeds are intended to be utilized for research and development, working capital, and general corporate purposes. This move reflects SELLAS' commitment to advancing its development of innovative therapies for cancer treatment.
Read more →SLSSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
SELLAS Life Sciences Group, Inc. announced a corporate update call scheduled for March 26, 2024, led by President and CEO Angelos Stergiou. The call will cover the Phase 3 REGAL clinical trial progress for its drug galinpepimut-S (GPS) targeting acute myeloid leukemia (AML) and present topline data from the Phase 2a study of SLS009. This indicates continued efforts in advancing their cancer therapies, with a focus on providing market updates on their clinical trials.
Read more →SLS▼ -29%on this newsshared move
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules 3/15/2024
SELLAS Life Sciences Group has announced a $20 million capital raise through a registered direct offering and a concurrent private placement. The company will issue 13,029,316 shares of common stock priced at $1.535 per share, along with warrants for the same amount. Proceeds will be utilized for research and development, working capital, and corporate purposes. The offering is subject to customary closing conditions and expected to close around March 19, 2024.
Read more →SLS▼ -29%on this newsshared move
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SELLAS Life Sciences Group has announced a registered direct offering and concurrent private placement, aiming to raise approximately $20 million through the sale of common stock and warrants. The offering is priced at $1.535 per share and is conducted under Nasdaq rules. The funds are intended for research, development activities, and general corporate purposes. The closing of this offering is expected around March 19, 2024, subject to customary conditions. LifeSci Advisors is acting as the sole placement agent for this transaction.
Read more →SLSSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
SELLAS Life Sciences Group has announced an executive leadership reorganization to better focus on its clinical programs and optimize resource allocation. Key executives, Robert Francomano and Barbara Wood, will be departing as the company aims to advance its clinical pipeline, particularly in oncology treatments. The company is also engaging a new commercial consultant to assist with various strategic initiatives. SELLAS is set to report on critical clinical trial data in the upcoming months, which will be pivotal for its growth and shareholder value.
Read more →SLSSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships 3/8/2024
SELLAS Life Sciences Group, Inc. has announced a reorganization of its executive leadership aimed at streamlining operations and prioritizing commercialization partnerships. Robert Francomano and Barbara Wood will be departing the company, while new leadership is being brought in to enhance operational compliance and market access strategies. The company's President emphasized the ongoing focus on advancing clinical programs and upcoming data from various trials. This restructuring is intended to optimize resources and drive shareholder value amidst inherent risks in oncology product development.
Read more →SLSSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
SELLAS Life Sciences announced promising Phase 1 data presentation for SLS009 at the 2024 ESH Conference, showing complete remission in r/r AML patients. The treatment demonstrated a favorable safety profile and achieved significant anti-tumor activity. Further data from the ongoing Phase 2a trial is anticipated, which aims to assess SLS009 in combination with standard therapy. This development marks a potential new avenue in treating acute myeloid leukemia.
Read more →SLSSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
SELLAS Life Sciences announced a schedule change for its presentation of SLS009 Phase 1 data related to acute myeloid leukemia at the 2024 European School of Haematology Conference in Stockholm. The presentation will now take place on March 1, 2024, at 12:55 pm CEST instead of March 3. Dr. Tapan Kadia from The University of Texas MD Anderson Cancer Center will present findings regarding the dose-escalation study. This event underscores SELLAS's ongoing efforts in developing innovative therapies for cancer treatment.
Read more →SLS▲ +12.2%on this news· ran to +28% by day 3
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
SELLAS Life Sciences Group has announced a publication in Oncotarget detailing the preclinical findings on its CDK9 inhibitor, SLS009. The research underscores SLS009's potential efficacy in treating hematologic malignancies through its ability to induce apoptosis in cancer cells. The company is optimistic about the ongoing clinical trials and expects to provide topline data from studies involving acute myeloid leukemia and peripheral t-cell lymphomas soon. This progress reinforces SLS009's position as a possible effective therapy for multiple cancer indications.
Read more →SLSSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
SELLAS Life Sciences announced the upcoming presentation of Phase 1 data from its SLS009 study targeting acute myeloid leukemia. The presentation will occur at the 2024 European School of Haematology Conference in Stockholm on March 3, 2024, led by Dr. Tapan Kadia from the MD Anderson Cancer Center. This marks a significant step in the development of SLS009, a CDK9 inhibitor, within the context of ongoing research in hematologic malignancies.
Read more →SLSSELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
SELLAS Life Sciences has received Fast Track Designation from the FDA for its drug SLS009, aimed at treating relapsed/refractory acute myeloid leukemia (AML). The Phase 2a study demonstrated promising results, with 89% of patients remaining alive and significant anti-leukemic effects observed in 87.5% of evaluable patients. Notably, two patients achieved complete remission and continue to show positive health outcomes. The company expects to report further data from the study in early Q1 2024.
Read more →SLS▼ -35.8%on this newsshared move
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering 1/4/2024
SELLAS Life Sciences has announced a public offering of 12,000,000 shares aimed at raising $9.0 million for the development of its oncology therapeutics. This offering includes warrants that will expire five years from issuance, promoting capital influx for the company's clinical programs. The closing of the offering is anticipated for January 8, 2024, assuming all customary conditions are met. Despite the potential benefits, the company acknowledges significant risks tied to product development and regulatory approval.
Read more →SLS▼ -35.8%on this newsshared move
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
SELLAS Life Sciences Group, Inc. has announced the pricing of a public offering to sell 12 million shares of common stock and corresponding warrants, anticipated to generate $9 million in gross proceeds. This offering is structured at a price of $0.75 per share and is expected to close on or about January 8, 2024. The company plans to use the funds raised from this offering to support its clinical and development programs focused on novel cancer therapies. The press release reinforces the need for investors to review detailed documents concerning the offering for better understanding.
Read more →SLS▼ -35.8%on this newsshared move
SELLAS Life Sciences Announces Proposed Public Offering
SELLAS Life Sciences has announced a proposed public offering of its common stock and warrants. The company aims to utilize the proceeds from the offering to fund ongoing operations, including the clinical development of its product candidates. The offering's completion is uncertain and hinges on market conditions, with no guarantees regarding the size or terms. SELLAS is pursuing this funding under an effective shelf registration statement previously filed with the SEC.
Read more →SLSSELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
SELLAS Life Sciences Group, Inc. has announced several corporate updates including an upcoming webinar and anticipated clinical milestones for 2024. The company expects interim analysis results for its Phase 3 REGAL study of Galinpepimut-S in AML patients and topline data from its Phase 2a SLS009 trial in the first quarter of 2024. The FDA has acknowledged SLS009 with Fast Track Designation and Orphan Drug Designations, indicating promising progress. Additionally, SELLAS reported positive patient responses in initial studies, suggesting the potential for their therapies in treating cancer.
Read more →SLSSELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma
SELLAS Life Sciences reported encouraging follow-up data from a Phase 1 trial evaluating galinpepimut-S (GPS) combined with nivolumab (Opdivo) in patients with advanced malignant pleural mesothelioma. The study achieved a median overall survival of 70.3 weeks in patients treated with the combination therapy. Additionally, a notable three-fold increase in survival was observed among patients with a GPS-specific immune response. The results underscore the potential of GPS as a significant treatment option in challenging cancer settings.
Read more →SLS▼ -5.7%on this news· ran to -16% by day 1shared move
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
SELLAS Life Sciences Group has announced that the FDA has granted Orphan Drug Designation for SLS009, a CDK9 inhibitor aimed at treating relapsed/refractory Peripheral T-cell Lymphomas (PTCL). The designation comes after a Phase 1 trial demonstrated a 36.4% clinical response rate in r/r PTCL patients, outperforming the current standard of care. Further evaluation of SLS009 is ongoing in a Phase 1b/2 trial, with top line data expected in the first half of 2024. This designation offers various development incentives, including tax credits and marketing exclusivity.
Read more →SLS▲ +14.2%on this news
SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
SELLAS Life Sciences Group announced the enrollment of the first patients in the 60 mg dose cohort of its Phase 2a clinical trial for the CDK9 inhibitor SLS009, targeting relapsed/refractory acute myeloid leukemia (AML). Following the completion of the 45 mg safety cohort, which showed no significant safety issues, the trial will examine the efficacy and safety of SLS009 in combination with other treatments. Early data from both the 45 mg and 60 mg cohorts are anticipated by the end of 2023, highlighting the potential of SLS009 as a viable treatment option for patients who have limited therapy options after failed venetoclax treatments.
Read more →SLSSELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
SELLAS Life Sciences Group, Inc. will host a corporate update webinar on January 3, 2024, at 8:30 a.m. ET. The CEO, Dr. Angelos Stergiou, will discuss the company's achievements in 2023 and provide an outlook for 2024. The webinar will feature discussions on the Phase 3 REGAL trial of galinpepimut-S and the clinical program for SLS009, a CDK9 inhibitor, by leading medical experts in the field.
Read more →SLSSELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
SELLAS Life Sciences announced a positive assessment from the Independent Data Monitoring Committee (IDMC) regarding the Phase 3 REGAL clinical trial for galinpepimut-S in acute myeloid leukemia. The IDMC recommended continuing the trial without any modifications and highlighted the integrity of the study. An update on survival data is expected before the next IDMC meeting in Q1 2024, indicating ongoing evaluation of the trial's progress. SELLAS remains optimistic about the potential of galinpepimut-S as a treatment option for AML.
Read more →SLSSELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
SELLAS Life Sciences has successfully reached its target enrollment in the Phase 3 REGAL trial for galinpepimut-S (GPS) in acute myeloid leukemia (AML) patients. The trial, which holds significant importance for both the company and the AML patient community, is expected to yield interim analysis results by the end of 2023 or early 2024. Following this achievement, further discussions with the FDA regarding the product's regulatory path indicate a positive outlook for the GPS program. The company emphasizes the promising scientific basis for GPS as a treatment option in this challenging medical setting.
Read more →SLSSELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)
SELLAS Life Sciences has received positive feedback from the FDA on its Chemistry, Manufacturing, and Controls (CMC) plans for its lead candidate, Galinpepimut-S (GPS). This feedback supports the company's strategy for a Biologics License Application (BLA) and represents a critical step in the approval process for the treatment of acute myeloid leukemia (AML). The FDA's agreement on the stability data generation plan enhances the commercial prospects for GPS, which is designed to target specific tumor proteins. The company is on track to complete enrollment for its Phase 3 REGAL study, with hopes to provide significant clinical benefits to AML patients.
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports Third Quarter 2023 Financial Results - Phase 3 REGAL Trial of Galinpepimut-S (GPS) on Track to Complete Enrollment ex-China in November 2023 - - Positive Initial
SELLAS Life Sciences has provided a business update highlighting several key developments, including positive topline results from the Phase 2a trial of SLS009 in acute myeloid leukemia (AML), where patients have shown promising responses. The company is on track to finalize enrollment for its Phase 3 REGAL trial of Galinpepimut-S (GPS) in AML by November 2023. Furthermore, SLS009 has received Orphan Drug and Fast Track designations from the FDA. The company plans to share further data and insights in the coming months, with a corporate update scheduled for December.
Read more →SLSSELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results
SELLAS Life Sciences has reported a business update alongside its Q3 2023 financial results, highlighting key advancements in its clinical trials. The Phase 2a results of SLS009 show positive outcomes in treating AML patients resistant to current therapies, and the FDA has granted Orphan and Fast Track designations for this drug. The REGAL Trial of Galinpepimut-S is expected to complete its enrollment in the coming weeks. While there are promising signs for SLS009, some aspects of its studies depend on future events which may influence timelines.
Read more →SLSSELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
SELLAS Life Sciences reported positive data from its Phase 1/2 trial of galinpepimut-S (GPS) in combination with Keytruda for patients with WT1+ platinum-resistant ovarian cancer. The combination resulted in a median overall survival of 18.4 months, significantly higher than historical data from standard treatments. Notably, the trial demonstrated the potential for improved immune responses, with a disease control rate of 50.1%. The study findings suggest that GPS may offer a compelling option in treating this challenging cancer indication.
Read more →SLS▼ -16.4%on this news
SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
SELLAS Life Sciences has announced a $4 million registered direct offering priced at-the-market under Nasdaq rules. The offering involves the sale of 3,652,300 shares to a single healthcare-focused institutional investor at a price of $1.0952 per share. The deal will also include warrants for the purchase of up to 3,652,300 additional shares at an exercise price of $0.9702. Closing of the transaction is anticipated around November 2, 2023, pending customary conditions.
Read more →SLS▲ +24%on this newsshared move
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
SELLAS Life Sciences has received Fast Track Designation from the FDA for its drug SLS009, aimed at treating relapsed/refractory Peripheral T-cell Lymphomas (PTCL). This designation signifies an expedited pathway to clinical review, as SLS009 demonstrated a clinical response rate of 36.4% in a Phase 1 trial, outperforming the current standard of care. The company plans to advance its clinical development in collaboration with GenFleet Therapeutics and is pursuing a potential Breakthrough Therapy designation from the FDA. An ongoing Phase 1b/2 trial in China will evaluate the drug further.
Read more →SLS▼ -7.9%on this news· ran to -25% by day 3
SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annual Global Meeting
SELLAS Life Sciences announced it will present final data from a Phase 1/2 trial of galinpepimut-S combined with pembrolizumab at the IGCS Annual Global Meeting in November 2023. The study focuses on patients with WT1-positive platinum-resistant advanced ovarian cancer. The results, which show promising activity of the treatment, will be made public during the meeting. Additionally, SELLAS plans to submit a detailed manuscript based on these findings in the first half of 2024.
Read more →SLSSELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia - SLS009 Is First CDK9 Inhibitor in Combination with AZA/VEN to Achieve Complete Response in AML Patient Resistant to Venetoclax
SELLAS Life Sciences announced promising initial data from its Phase 2a trial of SLS009, a CDK9 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. Positive results include one complete response and anti-leukemic effects observed in all participants. The trial also noted no significant safety concerns, enhancing the drug's profile as a viable treatment for patients resistant to venetoclax-based therapies. Future results from the recommended Phase 2 dose are anticipated later this quarter, potentially expanding treatment options for a challenging patient population.
Read more →SLS▼ -10.4%on this newsshared move
SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia - Enrollment ex - China Expected to be Completed in November 2023 - - Enrollment in China Expected to Comm
SELLAS Life Sciences has provided a positive update on its Phase 3 REGAL clinical trial for galinpepimut-S, indicating that enrollment outside China is expected to be completed in November 2023. Enrollment in China is set to begin this quarter, which will also activate milestone payments. The company has already enrolled enough patients for the upcoming interim analysis, expected later this year or early next year. However, enrollment in China faced delays due to supply-chain issues, highlighting potential risks in the timeline.
Read more →SLS▼ -15.5%on this newsshared move
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas
SELLAS Life Sciences Group has announced that its partner, GenFleet Therapeutics, has dosed the first patient in a Phase Ib/II trial for SLS009 (GFH009) aimed at treating relapsed/refractory Peripheral T-cell Lymphomas. This open-label trial, which will enroll up to 95 patients, seeks to evaluate the drug's safety and efficacy and may serve as a registrational study based on the outcomes. SLS009, a selective CDK9 inhibitor, has previously demonstrated clinical efficacy in related hematological malignancies. This initiative reflects SELLAS's commitment to advancing treatments for cancer patients globally.
Read more →SLSSELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia
SELLAS Life Sciences Group has received Orphan Drug Designation for its CDK9 inhibitor, SLS009, for the treatment of acute myeloid leukemia (AML). This designation emphasizes the potential of SLS009 to meet significant unmet medical needs in AML treatment. The drug has shown promising results in safety and efficacy through initial clinical studies, and the company aims to expedite its development with the support of this designation. Final data from ongoing studies are expected by the end of this year.
Read more →SLS▲ +6.7%on this news
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
SELLAS Life Sciences Group announced positive topline results from its Phase 1 dose-escalation trial of the CDK9 inhibitor SLS009 in relapsed/refractory lymphoma patients. Out of 52 enrolled patients, 96% were alive at the last assessment, with a 14.7% overall clinical response rate. The maximum tolerated dose was not reached, and all primary and secondary study objectives were met. The pharmaceutical company plans to advance SLS009 into Phase 2 trials later this year.
Read more →SLS▼ -6.8%on this newsshared move
SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference
SELLAS Life Sciences Group, Inc. announced its upcoming participation in the Cantor Fitzgerald Global Healthcare Conference, scheduled from September 26-28, 2023. The event will feature panel presentations and one-on-one investor meetings with the company's management team, including CEO Angelos Stergiou. This participation highlights SELLAS's focus on developing novel therapies for cancer indications and may enhance its visibility and engagement with potential investors.
Read more →SLSSELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications
SELLAS Life Sciences Group announced that the Independent Data Monitoring Committee (IDMC) has recommended the continuation of the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia without any modifications. The trial is expected to complete enrollment by Q4 2023, with an interim analysis anticipated to occur by late 2023 or early 2024. The IDMC praised the study's integrity and conduct, highlighting the positive momentum leading up to these significant milestones in the GPS development program.
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results First Patients Dosed in Phase 2a Clinical Trial of SLS009 (formerly GFH009) in Acute Myeloid Leukemia with Topline Data Expe
SELLAS Life Sciences Group has reported progress in its clinical trials, including the first dosing of patients in the Phase 2a study of SLS009 for acute myeloid leukemia (AML). The company anticipates topline data for SLS009 in the fourth quarter of 2023. Additionally, the Phase 3 REGAL study of galinpepimut-S is on track for an interim analysis by late 2023 or early 2024, reflecting the company's strategic focus on AML treatments. Financial results show a net loss increase, but expected milestone payments may improve liquidity.
Read more →SLSSELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma
SELLAS Life Sciences Group reported positive topline data from a Phase 1 trial of galinpepimut-S (GPS) combined with nivolumab (Opdivo) for advanced malignant pleural mesothelioma. The combination resulted in a 70.3 weeks median overall survival, significantly higher than the historical median of around 28 weeks for standard treatment. Additionally, a 30% disease control rate was achieved with no dose-limiting toxicities observed. However, 70% of patients experienced treatment-related adverse events.
Read more →SLSSELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia
SELLAS Life Sciences Group has announced the dosing of the first patient in its Phase 2a clinical trial for GFH009, a CDK9 inhibitor, in patients with relapsed/refractory acute myeloid leukemia. The study will evaluate the safety, tolerability, and efficacy of GFH009 when combined with venetoclax and azacitidine. Topline data from this trial is expected in the fourth quarter of 2023, following promising results from a Phase 1 study. This advancement reflects SELLAS' commitment to addressing unmet medical needs in difficult-to-treat AML patients.
Read more →SLSSELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting
SELLAS Life Sciences Group, Inc. announced the acceptance of its abstract for a poster presentation at the 2023 International Gynecologic Cancer Society Annual Meeting. The presentation will focus on a Phase 1/2 study of galinpepimut-S in combination with pembrolizumab for treating WT1+ platinum-resistant ovarian cancer. This meeting is scheduled for November 5-7, 2023, in Seoul, South Korea. The abstract will be published by IGCS on October 17, 2023, highlighting SELLAS's commitment to developing novel cancer therapies.
Read more →SLSSELLAS to Participate in Maxim Group Healthcare Virtual Conference
SELLAS Life Sciences Group, Inc. announced that its CEO, Angelos Stergiou, will participate in the Maxim Group Healthcare Virtual Conference on June 21, 2023. The company focuses on novel cancer therapies, including its lead product candidate galinpepimut-S, which targets the WT1 protein found in various tumors. Additionally, they are developing GFH009, a selective CDK9 inhibitor, for therapeutic use worldwide outside Greater China. However, the company acknowledges potential risks and uncertainties related to product development and regulatory approvals in its forward-looking statements.
Read more →SLSC O R P O R A T E P A R T I C I P A N T S Tara Sobierajski, Senior Manager, Client Success, LifeSci Events Angelos Stergiou, MD, SCD HC, Founder, President and Chief Executive Officer, Sellas Life Sciences Dragan Cicic,
Sellas Life Sciences provided an update on their GFH009 program during a recent conference call. The focus was primarily on the upcoming Phase 2a study targeting relapsed/refractory acute myeloid leukemia (AML). The company expressed optimism regarding FDA feedback on trial design and highlighted the drug's potential to improve treatment outcomes, especially in patients resistant to existing therapies. GFH009, a selective CDK9 inhibitor, could serve as a transformative therapy by complementing existing AML treatments.
Read more →SLSSELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
SELLAS Life Sciences announced the presentation of a trial in progress poster for its Phase 3 REGAL study of galinpepimut-S (GPS) at the ASCO Annual Meeting scheduled for June 2-6, 2023. The REGAL study, targeting acute myeloid leukemia, has received FDA agreement on all study parameters. An interim analysis is anticipated by the end of 2023 or early 2024. The poster will focus on the efficacy and safety of GPS maintenance monotherapy compared to the best available therapy for patients achieving complete remission post-salvage therapy.
Read more →SLSSELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia
SELLAS Life Sciences Group, Inc. plans to host a virtual expert panel on May 30, 2023, to discuss GFH009 and its potential impact on acute myeloid leukemia (AML). The panel will include notable hematology-oncology specialists who will evaluate the treatment landscape for relapsed and/or refractory AML. Additionally, the company is set to initiate a Phase 2a clinical trial of GFH009 in combination with venetoclax and azacitidine. This initiative is a significant step in addressing the unmet medical needs of AML patients.
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results Phase 1 Study of Novel, Highly Selective CDK9 Inhibitor GFH009 Successfully Completed for Patients with Acute Myeloid Leukemi
SELLAS Life Sciences reported a business update and financial results for Q1 2023, highlighting the successful completion of a Phase 1 study for GFH009, a CDK9 inhibitor for acute myeloid leukemia (AML). With 94% of patients enrolled alive and one patient achieving a durable remission, SELLAS is advancing to a Phase 2a trial expected to begin this quarter. Additionally, the ongoing Phase 3 REGAL study for Galinpepimut-S in AML continues as planned, with interim analysis expected by late 2023 or early 2024. Despite positive clinical outcomes, the company reported no licensing revenue and an increased net loss compared to the same quarter last year.
Read more →SLSSELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study
SELLAS Life Sciences announced promising topline data from its Phase 1 dose-escalation trial of GFH009 in patients with acute myeloid leukemia (AML). The trial included 72 high-risk advanced patients, where 94% demonstrated a survival benefit, and durable complete remission was noted in some patients. The recommended Phase 2 dose has been submitted to the FDA, with plans to initiate a Phase 2a trial using GFH009 in combination with other therapies. The trial showed significant tumor reduction and no major safety concerns, supporting further development of GFH009 in this challenging patient population.
Read more →SLS▲ +5%on this news
SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
SELLAS Life Sciences Group, Inc. announced the acceptance of an abstract for a presentation at the ASCO Annual Meeting, scheduled for June 2-6, 2023. The presentation will showcase a study examining the efficacy and safety of galinpepimut-S (GPS) as maintenance therapy in patients with acute myeloid leukemia who have achieved complete remission. This highlights the company's ongoing research into its innovative therapies for cancer treatment. The full abstract will be publicly available on May 25, 2023, ahead of the presentation.
Read more →SLS▼ -5.8%on this news
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
SELLAS Life Sciences Group has successfully completed the Phase I dose escalation trial of its CDK9 inhibitor GFH009 for acute myeloid leukemia (AML). The trial demonstrated significant anti-tumor activity with no observed dose limiting toxicities, allowing the company to plan a Phase 2a trial in combination with venetoclax and azacitidine. Topline data from this upcoming trial is expected in the fourth quarter of 2023.
Read more →SLSSELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
SELLAS Life Sciences announced that the Independent Data Monitoring Committee has given a favorable review of the Phase 3 REGAL trial of galinpepimut-S for acute myeloid leukemia. The trial is set to continue without changes, and an interim analysis is expected by the end of 2023 or early 2024. The IDMC will reconvene in Q3 2023 to assess the trial's progress further and has endorsed the addition of clinical sites in China as part of the initiative to advance the study. The primary endpoint of the trial focuses on overall survival in patients who have achieved complete remission following second-line salvage therapy.
Read more →SLSSELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update Phase 3 REGAL GPS AML Study on Track for Interim Analysis by Late 2023 Early 2024 Ongoing Phase 1 Study of CDK9 Inhibitor Suggest
SELLAS Life Sciences has reported its full-year financial results for 2022 and provided an update on its business and clinical trials. The Phase 3 REGAL trial for acute myeloid leukemia is on track for an interim analysis expected in late 2023 to early 2024. The company has successfully raised $20 million to bolster its cash position as it advances its pipeline, including promising results from the Phase 1 study of its CDK9 inhibitor. However, the company incurred a significant net loss, nearly doubling from the previous year.
Read more →SLSSELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
SELLAS Life Sciences has announced the publication of favorable data from a Phase 1 clinical trial studying the combination of galinpepimut-S (GPS) and nivolumab for relapsed ovarian cancer. The results, published in a peer-reviewed journal, indicate a remarkable 70% one-year progression-free survival rate among GPS-treated patients. The treatment also resulted in significant immune responses, with 91% of patients showing WT1-specific T-cell activity. These findings highlight the potential of GPS to improve clinical outcomes for ovarian cancer patients, particularly when used in combination with checkpoint inhibitors.
Read more →SLS▼ -53.7%on this news
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
SELLAS Life Sciences Group, Inc. has announced the pricing of a public offering of 7,220,217 shares of common stock at $2.77 per share, aiming to raise a total of $20.0 million. The offering, expected to close on February 28, 2023, will support the company's development efforts for innovative cancer therapies, including its lead candidate GPS. The offering is managed by Cantor Fitzgerald & Co. and is conducted under a shelf registration statement previously filed with the SEC. The company faces potential uncertainties associated with market conditions and the clinical development of their products.
Read more →SLS▼ -53.7%on this news
for the purpose of incorporating the information set forth herein by reference into the registration statement on Form S-3 (File No. 333-255318) that was filed by the registrant with the Securities and Exchange Commissio
The registrant has filed Exhibit 99.1 to incorporate information into its SEC registration statement on Form S-3, previously filed on April 16, 2021. The filing outlines the associated estimated costs and expenses linked to the security registration, totaling $258,000. This includes various fees such as legal, accounting, and printing expenses. The filing is part of the registrant's ongoing compliance with SEC regulations.
Read more →SLSSELLAS Life Sciences Announces Proposed Underwritten Public Offering
SELLAS Life Sciences Group, Inc. has announced the commencement of an underwritten public offering for shares and warrants of its common stock, with the offering managed by Cantor Fitzgerald & Co. The securities are being offered under a previously filed shelf registration statement with the SEC. While the company aims to leverage this capital for its cancer therapies, the completion and terms of the offering remain uncertain and are subject to market conditions.
Read more →SLSSELLAS Life Sciences to Host Key Opinion Leader Webinar on Galinpepimut-S Acute Myeloid Leukemia Program
SELLAS Life Sciences Group will host a key opinion leader webinar on January 31, 2023, to discuss their lead candidate, galinpepimut-S (GPS), in treating acute myeloid leukemia (AML). The event will feature insights from Dr. Omer Jamy, a principal investigator of the Phase 3 REGAL study. The webinar aims to explore the current treatment options for AML patients and highlight GPS's potential in targeting malignancies characterized by the WT1 antigen. A live Q&A session will follow the presentation.
Read more →SLSSELLAS Life Sciences Strengthens Leadership Team with Appointment of Vice President Head of Regulatory Affairs
SELLAS Life Sciences has appointed Andrew Elnatan as Vice President, Head of Regulatory Affairs, bolstering its leadership team. Elnatan comes with over 25 years of experience in regulatory affairs, specializing in oncology and immunology. His role will involve developing regulatory strategies for the company's clinical programs, particularly the galinpepimut-S (GPS) and GFH009 therapies. This strategic appointment comes at an important time as SELLAS prepares for upcoming regulatory milestones.
Read more →SLSSELLAS Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute
SELLAS Announces Positive Phase 1 Data with GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Anticancer Effects Observed Across Multiple Dose Levels in Both Acute
Read more →SLSSELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the
Read more →SLSSELLAS Life Sciences’ CDK9 Inhibitor GFH009 Selected for Pediatric Preclinical in Vivo Testing (PIVOT) Program in Pediatric Cancers by the National Cancer Institute
Studies are Supported and Funded Through Cooperative Agreement Grants from the National Cancer Institute GFH009 to be Evaluated Against Pediatric Solid Tumors and Leukemia Models at Eight Participating Research Institutions NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- SELLAS Lif
Read more →SLS▲ +8.8%on this newsshared move
SELLAS Life Sciences’ CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition in Small Cell Lung Cancer Murine Model
GFH009 exhibits robust activity against small cell lung cancer xenografts, both as monotherapy and in combination with PARP inhibitor olaparib Results support designating small cell lung cancer as first indication in planned solid cancer basket trial for GFH009 NEW YORK, Dec. 0
Read more →SLSSELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit
NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the
Read more →SLS▼ -12.2%on this news
C O R P O R A T E P A R T I C I P A N T S Allison Soss, Investor Relations, KCSA Strategic Communications Angelos Stergiou, MD, ScD hc, Founder, President & Chief Executive Officer, SELLAS Life Sciences Group M. Yair Lev
C O R P O R A T E P A R T I Allison Soss, Investor Relations, KCSA Strategic Communications Angelos Stergiou, MD, ScD hc, Founder, President & Chief Executive Officer, SELLAS Life Sciences Group M. Yair Levy, MD, Director of Hematologic Malignancies, Baylor University Medic
Read more →SLS▼ -44%on this newsshared move
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical Analysis Plan: Interim Analysis Now at 60 Events and Final Analysis Now at 80 Events – – 3D Medicines to Participate in REGAL Clinical Trial, Which Will Trigger Significant Milestone Payme
Read more →SLS▼ -44%on this newsshared move
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results - Cash Position of $21.3 Million as of
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2022 Financial Results - Cash Position of $21.3 Million as of September 30, 2022 - - Hosting Phase 3 REGAL Study Update Webcast Today at 8 30 a.m. ET - NEW YORK, November 14, 2022 - SELLAS Life Sciences Gr
Read more →SLSSELLAS Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer
- Median Overall Survival for GPS Combination (GPS in Combination with Keytruda) was 18.4 Months Compared to 13.8 months in a Checkpoint Inhibitor Single Agent Study in a Similar Patient Population Treated with Checkpoint Inhibitor Alone - - Median Progression Free Survival for
Read more →SLS▲ +9%on this news· ran to +25% by day 3
SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the
Read more →SLS▼ -17%on this newsshared move
SELLAS Life Sciences Provides Webcast Information for Phase 3 REGAL Study Update on November 14, 2022
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today provides webcast i
Read more →SLSSELLAS Life Sciences to Host Update Call on Phase 3 REGAL Study on November 14, 2022
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it
Read more →SLSSELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that 3D
Read more →SLSSELLAS Life Sciences Presents Poster at 2022 SOHO Meeting Highlighting Bioequivalence Data for GFH009 Formulations
GFH009 Formulation is Near Physiological pH, While Still Achieving Desired Effect - GFH009 at pH 6.0 Decreased Potential for Infusion Reaction and Made Dosing Better Tolerated After Multiple Doses or Long-time Infusion - NEW YORK, Sept. 29, 2022 (GLOBE NEWSWIRE) -- SELLAS Life
Read more →SLSSELLAS Life Sciences Announces Poster Presentation at the Society of Hematologic Oncology (SOHO) Annual Meeting
NEW YORK, Sept. 22, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced its upc
Read more →SLSInvestor Symposium on Galinpepimut - S
Investor Symposium on Galinpepimut - S September 15, 2022 NASDAQ: SLS NASDAQ: SLS Forward Looking Statements This presentation contains forward - looking statements. Such forward - looking statements can be identified by the use of the word s "expect," "believe," "will," "antici
Read more →SLSSELLAS Life Sciences to Participate in the Cantor Oncology, Hematology & HemeOnc Conference on September 28th
NEW YORK, Sept. 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that An
Read more →SLSSELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on September 15, 2022
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reminds the inves
Read more →SLSSELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
- Neuroendocrine Prostate Cancer is Growing Unmet Medical Need - NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies
Read more →SLSSELLAS Life Sciences' Announces Election of Katherine Bach Kalin to its Board of Directors - Ms. Kalin Joins the Board with Decades of Life Sciences and Healthcare Industry Experience
SELLAS Life Sciences' Announces Election of Katherine Bach Kalin to its Board of Directors - Ms. Kalin Joins the Board with Decades of and Healthcare Industry Experience - NEW YORK, August 16, 2022 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS'' or the "Company"
Read more →SLS▼ -5.6%on this newsshared move
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results - Reported Encouraging Updated Data in Q2 from Two Clinical Trials of Galinpepimut-S (GPS) in Combination with Checkpoint In
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2022 Financial Results - Reported Encouraging Updated Data in Q2 from Two Clinical Trials of Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors - - Provides Clinical Update for GFH009 Program -
Read more →SLSSELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
- Results Demonstrate Significant Anti-Tumor Effects on All Selected Cell Lines - - In Three of the Four Cell Lines, GFH009 Inhibited Cancer Growth by 90 to 100 Percent - NEW YORK, Aug. 09, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the
Read more →SLSSELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the
Read more →SLSSELLAS Life Sciences Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial
- No Dose-Limiting Toxicities Observed in Lymphoma and Acute Myeloid Leukemia Patients at All Dose Levels Studied To-Date - - Early Indications of Efficacy in Assessable Patients at Multiple Dose Levels - NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, I
Read more →SLSSELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo
NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel therapies for a broad range of cancer indications, today announced encouraging updat
Read more →SLSSELLAS Life Sciences to Present at the JMP Securities Life Sciences Conference on June 15th
NEW YORK, June 02, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Angelos Stergiou, MD, ScD. h.c, Presi
Read more →SLS▼ -8.8%on this news
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda in Patients with WT1+ Advanced Ovarian Cancer
- Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone - - Disease Control Rate for GPS combination (GPS plus Keytruda) is 53.9 percent compared to 37.2 percent in a checkpoint inhibitor single agent study in a similar patient population treated with ch
Read more →SLS▲ +12.6%on this news· ran to +39% by day 3
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update - Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - - $25 Million o
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update -Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - -$25 Million of Gross Proceeds from Capital Raise in April 2022 and $1 Mil
Read more →SLSSELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S
NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the
Read more →SLSSELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study
- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First Four Dose Levels - NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage cl
Read more →SLSSELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that an
Read more →SLSSELLAS Life Sciences Group, Inc. - Business Update and First Quarter 2022 Highlights Call
SELLAS Life Sciences Group, Inc. - Business Update and First Quarter 2022 Highlights Call, April 6, 2022 CORPORATE PARTICIPANTS Angelos M. Stergiou, CEO CONFERENCE CALL PARTICIPANTS Allison Soss, KCSA Strategic Communications Okay, let us begin with the forward looking state
Read more →SLSSELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights
– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – – Appointed Robert Francomano as Chief Commercial Officer – – Completed Enrollment in Phase 1/2 Study of Galinpepimut-S (GPS) in Combinat
Read more →SLS▼ -37.9%on this newsshared move
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering
NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pric
Read more →SLSSELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor
- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset - - Completion of Ongoing Phase 1 Trial in the United States/China Expected by Q4 2022 in Relapsed and/or Refractory Hematologic Malignancies - - SELLAS Expects to Initiate Phase 1 Study in
Read more →SLSSELLAS Life Sciences Expands Executive Team with Appointment of Robert Francomano as Chief Commercial Officer
NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced today that the C
Read more →SLSSELLAS Life Sciences Announces Final Court Approval of Settlement of Securities Litigation
NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on Feb
Read more →SLSSELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis Interim Data for 15 Evaluable Patients Expected in Mid-2022 with Final Data for up to 17 Patients in Q4 2022 NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) --
Read more →SLS▼ -6.9%on this newsshared move
SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China
NEW YORK, Jan. 26, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that an IN
Read more →SLSSELLAS Life Sciences Promotes John Burns to Senior Vice President, Finance and Chief Accounting Officer
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that John T
Read more →SLSSELLAS Life Sciences Announces Final Court Approval of Settlement of Derivative Litigation
NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that on Nov
Read more →SLS▼ -18.5%on this news
SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
SELLAS Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update NEW YORK, November 12, 2021 - SELLAS Life Sciences Group, Inc. (NASDAQ SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel can
Read more →SLSSELLAS Life Sciences to Participate in Upcoming Conferences in October 2021
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angelo
Read more →SLSSELLAS Life Sciences Announces Settlement of Derivative Litigation
SELLAS Life Sciences Announces Settlement of Derivative Litigation NEW YORK, September 23, 2021 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for
Read more →SLSSELLAS Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 28th
NEW YORK, Sept. 14, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angel
Read more →SLSSELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibit
SELLAS Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update Reported Promising Updated Clinical Data in Ongoing Clinical Trials of Galinpepimut-S (GPS) in Combination with PD-1 Inhibitors for Malignant Pleural Mesothelioma (MPM) and WT1+ Advan
Read more →SLSSELLAS Life Sciences to Host Virtual Investor Symposium on its Lead Asset, Galinpepimut-S, on August 17, 2021
Management Team to be Joined by Leading Cancer Researcher, Dr. Yair Levy, Director of Hematologic Malignancies at the Baylor University Medical Center, and Member of the REGAL Steering Committee NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ
Read more →SLSSELLAS Reports Promising Updated Clinical Data and Initial Immune Response Profiles from Ongoing Phase 1/2 Study of Galinpepimut-S (GPS) Combined with Keytruda for Treating WT1+ Advanced Ovarian Cancer
Updated Data Shows 100 Percent of Patients Alive and 45.5 Percent Continuing Investigational Therapy as of the Latest Follow-Up Immune Data Shows GPS Induced WT1-Specific Immune Responses with a Substantial Increase in Antigen-Reactive T-Lymphocytes Averaging +242% for CD8+ and
Read more →SLSSELLAS Reports Encouraging Updated Clinical Data from Ongoing Mesothelioma Study of Galinpepimut-S (GPS) Combined with Opdivo
Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeks New and Updated Clinical and Translational Data Ex
Read more →SLSSELLAS Life Sciences Announces Inclusion in Russell Microcap Index
NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that the Co
Read more →SLSSELLAS Life Sciences Group, Inc. Shareholder Update Call
Sciences Group, Inc. Life Sciences Group, Inc. - Shareholder Update Call, June 3, 2021 C O R P O R A T E P A R T I Allison Soss, Investor Relations Dr. Angelos Stergiou, Founder, President & Chief Executive Officer C O N F E R E N C E C A L L P A R T I C I P A N T S Jason
Read more →SLSSELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor Therapies
NEW YORK, May 27, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that the U.S
Read more →SLSSELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with
SELLAS Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update Received $1.0 Million Milestone Payment and Recognized $5.7 Million of License Revenue Under Exclusive License Agreement with 3D Medicines for Development and Commercialization of Gali
Read more →SLSSELLAS Life Sciences to Host Shareholder Update Call on June 3rd
NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will
Read more →SLSSELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194
SELLAS Life Sciences Reports Full Year 2020 Financial Results and Provides Business Update Entered into Exclusive License Agreement, with $7.5 Million Upfront License Fee and Potential to Receive up to an Additional $194.5 Million, with 3D Medicines for Development and Commercia
Read more →SLSSELLAS Life Sciences to Participate in the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17th
NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that Angel
Read more →SLSSELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones
- Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe - - License Agreement with 3D Medicines for Development and Commercialization of GPS in China Initiates Commercialization Strategy for GPS - - Balanc
Read more →SLSSELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones - Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe - - Lice
SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe - - License Agreement with 3D Medicines for Development and Commercializa
Read more →SLSSELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications - Early Data from Study of GPS in Combination with Keytruda in Patients w
SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications - Early Data from Study of GPS in Combination with Keytruda in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control
Read more →SLSSELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 Million
- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing - - Improved Cash Position Will Support Clinical Development Programs for Galinpepimut-S - NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc
Read more →SLSSELLAS Announces Pricing of $16.2 Million Registered Direct Offering
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering YORK, December 13, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapie
Read more →SLSSELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment – – Statistically Significant Difference of Duration of Immune Response of NPS vs. Control: p=0.000094 - – Data to be Presented Today at the San Antonio Breast Cancer Symposium - NEW YORK, Dec. 11, 2020 (
Read more →SLSSELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China - SELLAS to Potentially Receive Up To $202 Million, Inclu
SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China - SELLAS to Potentially Receive Up To $202 Million, Inclusive of $7.5 Million Upfront License Fee and $8 Million N
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results - Received IMPD Approval to Commence Enrollment in France for Pivotal Phase 3 Study of Galinpepimut-S in Acute Myeloid Leukem
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results - Received IMPD Approval to Commence Enrollment in France for Pivotal Phase 3 Study of Galinpepimut-S in Acute Myeloid Leukemia patients - - Strengthened Balance Sheet During Quarter
Read more →SLSSELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today annou
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results - Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market - - Clinical programs f
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results -Strengthened balance sheet in August 2020 with $9.2 million private placement priced at-the-market - -Clinical programs for galinpepimut-S, including phase 3 REGAL study, on track,
Read more →SLSSELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market - Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study - NEW YORK, July 31 2020 -- SELLAS Life Sciences Gro
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market - Proceeds to be used to fund the ongoing Phase 3 Acute Myeloid Leukemia REGAL study - NEW YORK, July 31 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a la
Read more →SLSSELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market
NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announ
Read more →SLSSELLAS to Host Virtual Annual Meeting of Stockholders
NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announc
Read more →SLSSELLAS Establishes Independent Data Monitoring Committee of Leading Clinical and Biostatistics Experts for Pivotal Phase 3 REGAL Clinical Trial
Independent Data Monitoring Committee (DMC) to Review and Evaluate Patient Safety and Efficacy Data for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second Remission Moshe Talpaz, M.D., Associate Director of Translational Research and Associ
Read more →SLSSELLAS Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update - Ongoing Clinical Trials Continue to Progress - NEW YORK, May 14 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SE
SELLAS Life Sciences Reports First Quarter 2020 Financial Results and Provides Business Update - Ongoing Clinical Trials Continue to Progress - NEW YORK, May 14 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmace
Read more →SLSSELLAS to Present at UBS Virtual Global Healthcare Conference
NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announc
Read more →SLSSELLAS Releases Annual Letter to Shareholders
NEW YORK, April 28, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today annou
Read more →SLSSELLAS Appoints Steering Committee of Leading Acute Myeloid Leukemia Experts for Its Ongoing Phase 3 REGAL Clinical Trial in AML
Steering Committee to Provide Scientific Oversight and Guidance for Pivotal Phase 3 Trial of Galinpepimut-S in Patients with Acute Myeloid Leukemia in Second Remission Hagop Kantarjian, MD, Professor and Chair of the Department of Leukemia at The University of Texas - MD Anderso
Read more →SLSSELLAS Announces Positive Antigen-Specific Immune Response Data for Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast from Phase 2 VADIS Study
NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today annou
Read more →SLSSELLAS Life Sciences Reports Full Year 2019 Financial Results and Provides Business Update NEW YORK, March [13], 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical b
SELLAS Life Sciences Reports Full Year 2019 Financial Results and Provides Business Update NEW YORK, March [13], 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of nove
Read more →SLSSELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
- Final analysis shows statistically significant median overall survival of 21 months in patients who received GPS compared to previously reported 5.4 months in the control arm (p-value < 0.02) - - Data provides additional support for ongoing pivotal Phase 3 REGAL study of GPS i
Read more →SLSSELLAS Life Sciences Provides Regulatory Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC) Following FDA Feedback
NEW YORK, Feb. 14, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announ
Read more →SLSSELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo ) in Patients with Malignant Pleural Mesothelioma (MPM)
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announ
Read more →SLSSELLAS Names Dragan Cicic, MD, as Senior Vice President, Clinical Development
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announ
Read more →SLSSELLAS Highlights Clinical Development Progress and Expected 2020 Milestones
- Phase 3 Galinpepimut-S (GPS) Acute Myeloid Leukemia (AML) Study Open for Enrollment and Patient Screening Underway - - Regulatory Feedback Regarding Nelipepimut-S (NPS) in Triple Negative Breast Cancer Expected within Q1 2020 - - Company to Present at Biotech Showcase™ on Mon
Read more →SLSSELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-Market
SELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-Market NEW YORK, January 9, 2020 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of nove
Read more →SLSSELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML)
-- Study Open for Enrollment and Patient Screening Underway -- NEW YORK, Jan. 08, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immun
Read more →SLSSELLAS to Present at Biotech Showcase™
NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announ
Read more →SLSSELLAS to Present at the 12th Annual LD Micro Main Event
NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announ
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results - Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End - -Cl
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results - Phase 3 Registrational Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) on Track to Initiate by Year End - -Clinically Significant Follow-up Data from Phase 1 Trial Con
Read more →SLSSELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced t
Read more →SLSSELLAS Announces Reverse Stock Split
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced t
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports Second Quarter 2019 Financial Results - Multiple Clinical Milestones and Data Sets Expected by Year End / Q1 2020 - - Company to Host its First R&D Investor Day i
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2019 Financial Results NEW YORK, August 14, 2019 -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) ("SELLAS" or the "Company"), a late-stage biopharmaceutical company focused on the development of novel canc
Read more →SLSSELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast
NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced c
Read more →SLSSELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study
- Study is Being Conducted with Merck Under a Clinical Trial Collaboration and Supply Agreement - - Trial to Enroll Patients with Ovarian, Colorectal, Triple Negative Breast, and Small Cell Lung Cancers and Acute Myeloid Leukemia - - First Clinical Data Expected in First Quarte
Read more →SLSSELLAS Life Sciences Announces Closing of $15 Million Public Offering
NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of indications, today announced the closin
Read more →SLSSELLAS Life Sciences Announces Pricing of $15 Million Public Offering 6/14/2019
SELLAS Life Sciences Announces Pricing of $15 Million Public Offering NEW YORK, June 14, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a clinical stage biopharmaceutical company focused on the development of novel cancer
Read more →SLSSELLAS Life Sciences Announces Pricing of $15 Million Public Offering
NEW YORK, June 14, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications, today announce
Read more →SLSSELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019
NPS-Specific Cytotoxic T-Lymphocyte Mean Frequencies Increased by 2.86-fold Compared to Baseline at 30 months Notable Correlation Between Progressive Increase of NPS-Specific Cytotoxic T-Lymphocyte in NPS Plus Trastuzumab Patient Cohort and Remaining Clinically Relapse-Free Over
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results Company to Present Data at Upcoming American Society of Clinical Oncology (ASCO) Annual Meeting
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results Company to Present Data at Upcoming American Society of Clinical Oncology (ASCO) Annual Meeting NEW YORK, May 15, 2019 -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or t
Read more →SLSSELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)
Initiation of Phase 1 Clinical Trial in Relapsed or Refractory MPM Expected in the Second Quarter of 2019 Previous Combination Study of GPS and Nivolumab Given After Salvage Chemotherapy in Ovarian Cancer Patients Showed 1-year Progression-Free Survival Rate of 70% and Induction
Read more →SLSSELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update
SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update NEW YORK, NY, March 22, 2019 - SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel cancer immun
Read more →SLSSELLAS Life Sciences Announces Presentation of Final Data Analysis from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2019 ASCO-SITC Clinical Immuno-Oncology Meeting
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced
Read more →SLSin its Current Report on Form 8-K filed on
SELLAS Life Sciences Announces Review of Strategic Alternatives Phase 1/2 basket trial of lead clinical candidate, galinpepimut-S (GPS), plus Keytruda (pembrolizumab) ongoing; Phase 3 registrational study for GPS monotherapy in acute myeloid leukemia (AML) planned Discussions o
Read more →SLSSELLAS Life Sciences Announces Review of Strategic Alternatives
Phase 1/2 basket trial of lead clinical candidate, galinpepimut-S (GPS), plus Keytruda® (pembrolizumab) ongoing; Phase 3 registrational study for GPS monotherapy in acute myeloid leukemia (AML) planned Discussions on development path for nelipepimut-S (NPS) ongoing with U.S. Foo
Read more →SLSSELLAS Life Sciences Provides Galinpepimut-S and Nelipepimut-S Program Update
Dr. Richard Maziarz and Dr. Roisin O'Cearbhaill Named Co-Principal Investigators for Galinpepimut-S (GPS) – Pembrolizumab Phase 1/2 Basket Trial Immune Response Data from the Phase 2b Nelipepimut-S (NPS) plus Trastuzumab Combination Study Demonstrates Antigen-Specific T-cell Clo
Read more →SLSSELLAS Life Sciences to Present at the 2019 BIO CEO & Investor Conference
NEW YORK, Jan. 31, 2019 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced t
Read more →SLSSELLAS Life Sciences Provides Update on Late-Stage Immunotherapy Clinical Development Pipeline
Aligned with FDA on Phase 3 Registration-Enabling Trial for Galinpepimut-S (GPS) in Acute Myeloid Leukemia; Trial Expected to Start in Q2 2019 Enrollment of Phase 1/2 Basket Trial of GPS plus Keytruda® (pembrolizumab) Initiated; Interim Analysis Anticipated in Q4 2019 Construct
Read more →SLSSELLAS Life Sciences Announces Additional Positive Triple Negative Breast Cancer (TNBC) Subgroup Data from Phase 2b Study of Nelipepimut-S Plus Trastuzumab at the 2018 San Antonio Breast Cancer Symposium
Clinically Meaningful and Statistically Significant Decrease in the Frequency of Clinically Detected Recurrences in the TNBC Cohort Treated with Nelipepimut-S plus Trastuzumab (p=0.004) Specific Benefit in Four Predefined Subgroups of TNBC Patients Receiving Nelipepimut-S plus T
Read more →SLSSELLAS to Present Further Correlative Data from Phase 2b Trial of NeuVax + Herceptin at the 2018 San Antonio Breast Cancer Symposium
NEW YORK, Nov. 30, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced t
Read more →SLSSELLAS Life Sciences Announces Expedited Development Path for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Following Feedback from FDA
Agreement on new open-label randomized registrational Phase 3 study in patients in second complete remission (CR2) poised to reduce sample size, time to primary endpoint and costs Fast-Track and Orphan Drug designations for GPS in AML continue to apply NEW YORK, Nov. 28, 2018 (
Read more →SLSSELLAS Life Sciences Announces Completion of Enrollment in Phase 2 Randomized Controlled Clinical Study of Nelipepimut-S Plus Trastuzumab in High-risk, High-expression HER2 Breast Cancer Patients
Data Expected in Fourth Quarter of 2019 Second Clinical Study of Nelipepimut-S Plus Trastuzumab After Recently Announced Positive Phase 2b Study in Low-expression HER2 or Triple Negative Breast Cancer Study supported by SELLAS and the Department of Defense's Congressionally Dir
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports Third Quarter 2018 Financial Results
Conference call today at 8:00 a.m. ET NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of
Read more →SLSSELLAS Life Sciences Announces Settlement of Counterclaims Against JGB (Cayman) Newton, Ltd. for $6.6 Million Payment by JGB
Follows Dismissal by Court of All Claims Against SELLAS Debenture and All Security Interests Held by JGB Terminated NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company
Read more →SLSSELLAS Life Sciences Announces Additional Data Showing Consistent Clinical Effect Across HLA Allele Subgroups in Triple Negative Breast Cancer (TNBC) Patients Treated with Nelipepimut-S Plus Trastuzumab Presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
Final data from Phase 2b clinical trial of nelipepimut-S (NeuVax™) in combination with trastuzumab (Herceptin®) were previously presented at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting Clinically meaningful and statistically significant benefit in the HL
Read more →SLSSELLAS Life Sciences to Provide Third Quarter 2018 Financial Results and Corporate Update on November 15, 2018
NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced th
Read more →SLSSELLAS Life Sciences Announces Positive Final Data in Triple Negative Breast Cancer Patients from Phase 2b Clinical Trial of Nelipepimut-S (NeuVax™) in Combination with Trastuzumab (Herceptin ) Presented at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting
Clinically and statistically significant efficacy in the triple negative breast cancer cohort with a p-value of 0.013 and a 75.2% reduction in risk of relapse or death in favor of investigational nelipepimut-S plus trastuzumab arm Clinically and statistically significant efficac
Read more →SLSSELLAS to Host Conference Call Following Oral Presentation of Phase 2b Results of NeuVax™ + Herceptin to Prevent Breast Cancer Recurrence at the European Society for Medical Oncology (ESMO) 2018 Annual Meeting
Interim and Updated Final Clinical Data to be Presented Conference Call on October 22, 2018 at 8:00 a.m. ET NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused
Read more →SLSSELLAS to Present Data from Phase 2b Trial of NeuVax + Herceptin at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
NEW YORK, Oct. 02, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced th
Read more →SLSSELLAS Life Sciences to Present at the 2018 Cantor Global Healthcare Conference
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced t
Read more →SLSSELLAS Receives Orphan Medicinal Product Designation Approval by the Committee for Orphan Medicinal Products of the European Medicines Agency for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
NEW YORK, Sept. 13, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced t
Read more →SLSSELLAS Life Sciences Provides Business Update and Reports Second Quarter 2018 Financial Results
NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today provided a b
Read more →SLSSELLAS To Present Data from Phase 2b Trial of NeuVax + Herceptin at Upcoming European Society for Medical Oncology (ESMO) 2018 Meeting
Oral Presentation of NeuVax + Herceptin in the Adjuvant Treatment of Triple-Negative Breast Cancer Conference Scheduled for October 19-23, 2018 in Munich, Germany NEW YORK, July 23, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company
Read more →SLSSELLAS Receives Fast Track Designation from FDA for Galinpepimut-S for the Treatment of Patients with Multiple Myeloma
NEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced tha
Read more →SLSmay contain forward-looking statements that reflect our current views with respect to our development programs, business strategy, business plan, financial performance and other future events. These statements include fo
You should consider carefully the risks and uncertainties described below, together with all of the other information in the Company s reports filed with the SEC. We operate in a dynamic and rapidly changing industry that involves numerous risks and uncertainties. The risks and
Read more →SLSSELLAS Life Sciences Announces Closing of $24.2 Million Public Offering
NEW YORK, July 16, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced th
Read more →SLSSELLAS Life Sciences Announces Pricing of Upsized $24.2 Million Public Offering
NEW YORK, July 12, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced th
Read more →SLSSELLAS Life Sciences Announces Proposed Public Offering of Common Stock
NEW YORK, June 26, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the launch of an unde
Read more →SLSSELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018
1-year progression-free survival (PFS) rate of 70% with induction of serum levels of WT1 Antigen-Specific Immunoglobulin G (IgG) in 86% of patients treated with GPS in combination with programmed cell death protein-1 (PD-1) inhibition No serious adverse events observed Data sup
Read more →SLSSELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients
Phase 2b trial met key clinical objectives and is being discontinued early by the sponsor Clinical and regulatory meetings held at the American Society of Clinical Oncology (ASCO) conference Dr. Jeffrey S. Weber, preeminent immuno-oncology expert, appointed Chairman of Scientif
Read more →SLSSELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
NEW YORK, May 17, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS) today announced that data from the Company’s ongoing Phase 1/2 study of galinpepimut-S (GPS) in combination with Bristol Myers Squibb’s nivolumab in patients with Wilms Tumor 1 + ova
Read more →SLSSELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM)
NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that the U.S. Food and Drug Administrati
Read more →SLSSELLAS Life Sciences Completes Second Tranche of $10,700,000 Private Placement
NEW YORK, May 02, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or “the Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the closing of the sec
Read more →SLSSELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the appointment of Gene Mack as Chief F
Read more →SLSSELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results
SELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results NEW YORK, NY, April 16, 2018 SELLAS Life Sciences Group Inc. (Nasdaq: SLS) ( SELLAS ), a clinical-stage biopharmaceutical company focused on novel ca
Read more →SLSSELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Herceptin in HER2 1+/2+ Breast Cancer Patients
Clinically meaningful activity in favor of investigational nelipepimut-S (NeuVax) + Herceptin arm Clinically and statistically significant efficacy in triple negative breast cancer (TNBC) cohort; p=0.023 NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group In
Read more →SLSSELLAS Life Sciences Announces Appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the appointment of Barbara A. Wood as E
Read more →SLSSELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting
- Galinpepimut-S (GPS) induced immune activation against Wilms tumor-1 (WT1) antigen as well as multifunctional cross-epitope T-cell reactivity in patients with aggressive multiple myeloma - Correlation noted between clinical and immune responses with promising progression free
Read more →SLSSELLAS Life Sciences Group Announces Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering Composition of Matter for WT-1 Peptides
NEW YORK, March 15, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) (“SELLAS” or the “Company”), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that the U.S. Patent
Read more →SLSSELLAS Life Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference
NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c.,
Read more →SLSSELLAS Life Sciences Announces $10,700,000 Private Placement - Financing Will Support Advancement of its Late-Stage Immuno-Oncology Pipeline - - Lead Candidate, Galinpepimut-S (GPS), On-Target for Initiation of Phase 3 A
SELLAS Life Sciences Announces $10,700,000 Private Placement - Financing Will Support Advancement of its Late-Stage Immuno-Oncology Pipeline - - Lead Candidate, Galinpepimut-S (GPS), On-Target for Initiation of Phase 3 Acute Myeloid Leukemia (AML) Study and Phase 1/2 Basket Tr
Read more →SLSSELLAS Life Sciences to Present at the 30th Annual ROTH Conference
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced that Angelos Stergiou, M.D., ScD h.c.,
Read more →SLSSELLAS Life Sciences to Present at Two Upcoming February Investor Conferences
- BIO CEO & Investor Conference on February 13 - - RBC Capital Markets Healthcare Conference on February 21 - NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a development-stage biopharmaceutical company focused on novel cance
Read more →SLSSELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting
NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (SELLAS) today announced that an abstract highlighting the detailed description of antigen-specific immune responses and correlation thereof with clinical effects over time has been accepted
Read more →SLSSELLAS Life Sciences Group Successfully Completes Business Combination with Galena Biopharma
HAMILTON, Bermuda and NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (SELLAS Inc.) today announced that the proposed merger of the businesses of SELLAS Life Sciences Group Ltd. (SELLAS Ltd.) and Galena Biopharma, Inc. (Galena) has closed
Read more →SLSGalena Biopharma, Inc. Stockholders Approve Business Combination with SELLAS Life Sciences Group, Ltd; Board Sets Reverse Stock Split Ratio San Ramon, California
Galena Biopharma, Inc. Stockholders Approve Business Combination with SELLAS Life Sciences Group, Ltd; Board Sets Reverse Stock Split Ratio San Ramon, California, December 29, 2017 Galena Biopharma, Inc. (NASDAQ: GALE) ( Galena ) announced today that its stockholders approved
Read more →SLSGalena Will Adjourn Special Meeting until Friday
Galena Will Adjourn Special Meeting until Friday, December 29, 2017, Urges Stockholders to Vote San Ramon, California, December 14, 2017 Galena Biopharma, Inc. (NASDAQ: GALE), ( Galena ) announced today that its special meeting of stockholders ( Special Meeting ), scheduled for
Read more →SLSGalena Biopharma Reports Third Quarter 2017 Financial Results
Galena Biopharma Reports Third Quarter 2017 Financial Results San Ramon, California, November 9, 2017- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financia
Read more →SLSSELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA Initiation of a Phase 1/2 Combination Clinical Trial with Galinpepimut-S and KEYTRUDA (pembrolizumab) A
SELLAS Enters into a Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc., Kenilworth, N.J., USA Initiation of a Phase 1/2 Combination Clinical Trial with Galinpepimut-S and KEYTRUDA (pembrolizumab) Across Various Indications Expected in 1H, 2018 and New
Read more →SLSGalena Biopharma Announces Completion of Enrollment in Two NeuVax (nelipepimut-S) Clinical Trials in Combination with Trastuzumab Interim efficacy analysis expected in Q1, 2018 for Phase 2b in HER2 1+/2+ patients San Ram
Galena Biopharma Announces Completion of Enrollment in Two NeuVax (nelipepimut-S) Clinical Trials in Combination with efficacy analysis expected in Q1, 2018 for Phase 2b in HER2 1+/2+ patients San Ramon, California, September 28, 2017 Galena Biopharma, Inc. (NASDAQ: GALE), a
Read more →SLSMM-252 Galinpepimut-S, a Wilms tumor protein 1 (WT1)-targeting immuno-oncology treatment, induces specific, robust, and durable immune responses (IRs) in patients with high-risk (HR) multiple myeloma (MM) Guenther Koehne
MM-252 Galinpepimut-S, a Wilms tumor protein 1 (WT1)-targeting immuno-oncology treatment, induces specific, robust, and durable immune responses (IRs) in patients with high-risk (HR) multiple myeloma (MM) Guenther Koehne1,2*, Sean Devlin3, Neha Korde2, Sham Mailankody2, Heather
Read more →SLSGalena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership San Ramon, California
Galena Biopharma and BioVascular, Inc. Reaffirm GALE-401 Partnership San Ramon, California, September 11, 2017- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today announced it
Read more →SLSGalena Biopharma Reports Second Quarter 2017 Financial Results
Galena Biopharma Reports Second Quarter 2017 Financial Results San Ramon, California, August 14, 2017- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financia
Read more →SLSGalena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group Merger to create a late-stage, NASDAQ-listed company focused on developing novel immune therapies for various types of cancer SELLAS lead asse
Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group SAN RAMON, CA, HAMILTON, Bermuda, and NEW YORK, NY, August 8, 2017 Galena Biopharma, Inc. (NASDAQ: GALE) and SELLAS Life Sciences Group Ltd, a privately-held, oncology-focused, clinical stage biopharm
Read more →SLSGalena Biopharma Reports First Quarter 2017 Financial Results
Galena Biopharma Reports First Quarter 2017 Financial Results San Ramon, California, May 10, 2017- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet medical needs, today reported its financial re
Read more →SLSGalena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update
Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update San Ramon, California, March 15, 2017- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unme
Read more →SLSGalena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim Chief Executive Officer San Ramon, California
Galena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim Chief Executive Officer San Ramon, California, February 21, 2017- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing hematology and oncology therapeutics that address unmet me
Read more →SLSGalena Biopharma Announces the Resignation of its President and Chief Executive Officer and the Evaluation of Strategic Alternatives San Ramon, California
Galena Biopharma Announces the Resignation of its President and Chief Executive Officer and the Evaluation of Strategic Alternatives San Ramon, California, January 31, 2017- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and comme
Read more →SLSGalena Biopharma Reports Third Quarter 2016 Financial Results and Provides a Corporate Update
Galena Biopharma Reports Third Quarter 2016 Financial Results and Provides a Corporate Update San Ramon, California, November 9, 2016 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncolog
Read more →SLSGalena Biopharma Appoints Stephen F.
Galena Biopharma Appoints Stephen F. Ghiglieri as Executive Vice President and Chief Financial Officer San Ramon, California, November 3, 2016- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of hematology and
Read more →SLSGalena Biopharma Reports Second Quarter 2016 Financial Results and Provides a Corporate Update
Galena Biopharma Reports Second Quarter 2016 Financial Results and Provides a Corporate Update San Ramon, California, August 9, 2016 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology
Read more →SLSGalena Biopharma Announces Pricing of Registered Direct Offering San Ramon, California
Galena Biopharma Announces Pricing of Registered Direct Offering San Ramon, California, July 8, 2016 Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major medica
Read more →SLSGalena Biopharma Discontinues NeuVax (nelipepimut-S) Phase 3, PRESENT Interim Analysis based on Independent Data Monitoring Committee Recommendation San Ramon, California
Galena Biopharma Discontinues NeuVax (nelipepimut-S) Phase 3, PRESENT Interim Analysis based on Independent Data Monitoring Committee Recommendation San Ramon, California, June 29, 2016- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the developm
Read more →SLSGalena Biopharma Appoints Mary Ann Gray, Ph.D., to its Board of Directors
Galena Biopharma Appoints Mary Ann Gray, Ph.D., to its Board of Directors San Ramon, California, April 26, 2016- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address m
Read more →SLSGalena Biopharma Reports Fourth Quarter and Year End 2015 Financial Results and Provides a Corporate Update
Galena Biopharma Reports Fourth Quarter and Year End 2015 Financial Results and Provides a Corporate Update San Ramon, California, March 10, 2016 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted o
Read more →SLSGalena Biopharma Announces Proposed Settlement of Derivative Litigation
Galena Biopharma Announces Proposed Settlement of Derivative Litigation San Ramon, California, February 16, 2016- Galena Biopharma, Inc. (the "Company"), (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeut
Read more →SLSGalena Biopharma Announces Proposed Public Offering of Common Stock and Warrants San Ramon, California
Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants San Ramon, California, January 6, 2016 Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that a
Read more →SLSGalena Biopharma Announces a Change to its Board of Directors
Galena Biopharma Announces a Change to its Board of Directors San Ramon, California, December 24, 2015 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unm
Read more →SLSThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Galena Biopharma to Sell Zuplenz (ondansetron) Oral Soluble Film, Completing Divestiture of Commercial Operations Zuplenz to be Sold to Midatech Pharma Plc for a potential of $23.65 million net payable to Galena Biopharma San Ramon, California, December 18, 2015- Galena Biophar
Read more →SLSGalena Biopharma Announces Departure of Chief Financial Officer
Galena Biopharma Announces Departure of Chief Financial Officer San Ramon, California, December 11, 2015- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major un
Read more →SLSK Exhibit-99.1 GALENA BIOPHARMA, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND OTHER FINANCIAL INFORMATION In order to provide Galena Biopharma, Inc. ("we," "us," "our," "Galena" or the "company") with the flexibil
GALENA BIOPHARMA, INC. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS AND OTHER FINANCIAL INFORMATION In order to provide Galena Biopharma, Inc. ("we," "us," "our," "Galena" or the "company") with the flexibility to file with the Securities and Exchange Commission (the "Commission
Read more →SLSGalena Biopharma Completes Divestiture of Abstral (fentanyl) Sublingual Tablets as Part of Strategic Focus on its Immunotherapy Pipeline
Galena Biopharma Completes Divestiture of Abstral (fentanyl) Sublingual Tablets as Part of Strategic Focus on its Immunotherapy Pipeline Total transaction value of up to $12 million with $8 million cash upfront and an additional $4 million based on achievement of certain sales m
Read more →SLSGalena Biopharma Reports Third Quarter 2015 Financial Results and
Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on its Clinical Development Programs with Planned Divestiture of the Commercial Business San Ramon, California, November 9, 2015 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceuti
Read more →SLSGalena Biopharma Appoints Bijan Nejadnik, M.D., as Executive Vice President and Chief Medical Officer
Galena Biopharma Appoints Bijan Nejadnik, M.D., as Executive Vice President and Chief Medical Officer San Ramon, California, October 30, 2015- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeu
Read more →SLSGALE-2015.08.06 EX99.1 Galena Biopharma Reports Second Quarter 2015 Financial Results Completed over-enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial and presented encouraging data for
Galena Biopharma Reports Second Quarter 2015 Financial Results Portland, Oregon, August 6, 2015 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across
Read more →SLSGALE-2015.05.07 EX99.1 Galena Biopharma Reports First Quarter 2015 Financial Results Completed enrollment in the NeuVax Phase 3 PRESENT breast cancer immunotherapy clinical trial Commercial programs continue on track Abs
Galena Biopharma Reports First Quarter 2015 Financial Results Portland, Oregon, May 7, 2015 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the
Read more →SLSGalena Biopharma Announces Proposed Public Offering of Common Stock and Warrants Portland, Oregon
Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants Portland, Oregon, March 12, 2015 Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medi
Read more →SLSGALE-2015.03.05 EX99.1 Galena Biopharma Reports Fourth Quarter and Year End 2014 Financial Results Cancer immunotherapy programs - NeuVax (nelipepimut-S) and GALE-301 - made significant advancements in 2014 Achievement o
Galena Biopharma Reports Fourth Quarter and Year End 2014 Financial Results Portland, Oregon, March 5, 2015 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical n
Read more →SLSGALE-2015.02.09 EX99.1 Galena Biopharma Enrolls 700 th Patient in NeuVax (nelipepimut-S) Phase 3 PRESENT Clinical Trial Key PRESENT trial enrollment milestone achieved Over-enrollment planned with expected completion nea
Galena Biopharma Enrolls 700th Patient in NeuVax (nelipepimut-S) Phase 3 PRESENT Clinical Trial Portland, Oregon, February 9, 2015- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that add
Read more →SLS11.20.2014 Galena Biopharma, Inc. announces Purchase Agreement for up to $55.0 Million with Lincoln Park Capital Fund, LLC Initial Purchase of $5.0 Million at $2.00 per share, 9% higher than the market clos
Galena Biopharma, Inc. announces Purchase Agreement for up to $55.0 Million with Lincoln Park Capital Fund, LLC Portland, Ore., November 20, 2014- Galena Biopharma, Inc. ("Galena" or the "Company") (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innova
Read more →SLSGalena Biopharma Reports Third Quarter 2014 Results
Galena Biopharma Reports Third Quarter 2014 Results Portland, Oregon, November 3, 2014 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance c
Read more →SLSGalena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer Portland, Oregon
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer Portland, Oregon, August 21, 2014- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that addres
Read more →SLSGalena Biopharma Reports Second Quarter 2014 Results
Galena Biopharma Reports Second Quarter 2014 Results Portland, Oregon, August 11, 2014- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance ca
Read more →SLSGalena Biopharma Enters into Definitive Agreement to License
Galena Biopharma Enters into Definitive Agreement to License U.S. Rights for Zuplenz (ondansetron) Oral Soluble Film Portland, Oregon, July 22, 2014- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology
Read more →SLSGalena Biopharma Reports First Quarter 2014 Results
Galena Biopharma Reports First Quarter 2014 Results Portland, Oregon, May 6, 2014- Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care,
Read more →SLSGalena Biopharma Reports Fourth Quarter and Year End 2013 Results
Galena Biopharma Reports Fourth Quarter and Year End 2013 Results Portland, Oregon, March 17, 2014- Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to adva
Read more →SLSDr. Reddy's Partnership Galena Biopharma and Dr. Reddy's Announce Strategic Partnership for NeuVax in India Galena licenses commercial rights to Dr. Reddy's for NeuVax (nelipepimut-S) in breast and gastric cancers Dr. Re
Galena Biopharma and Dr. Reddy's Announce Strategic Partnership for NeuVax in India Portland, Oregon, and Hyderabad, India, January 14, 2013- Galena Biopharma (NASDAQ: GALE) and Dr. Reddy's Laboratories Ltd. (NYSE: RDY) today announced a strategic development and commercializat
Read more →SLSMills Pharma Acquisition Press Release Galena Biopharma Acquires Mills Pharmaceuticals, LLC Acquisition adds GALE-401 (Anagrelide CR) to expand Galena's product pipeline. Phase 2 clinical trial expected to begin in mid-2
Galena Biopharma Acquires Mills Pharmaceuticals, LLC Portland, Oregon, January 13, 2014-Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer c
Read more →SLSGALE-2013.09.30 EX99.1 Galena Biopharma Reports Third Quarter 2013 Results Portland, Oregon
Galena Biopharma Reports Third Quarter 2013 Results Portland, Oregon, November 6, 2013- Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer c
Read more →SLSClosing Press Release Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants Portland, Oregon
Galena Biopharma Announces Closing of Public Offering of Common Stock and Warrants Portland, Oregon, September 18, 2013 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major
Read more →SLSPublic Offering Announcement Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants Portland, Oregon
Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants Portland, Oregon, September 12, 2013 - Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company focused on developing and commercializing innovative, targeted oncology treatments to addres
Read more →SLSGalena Biopharma Reports Second Quarter 2013 Financial Results Galena to generate sales revenue in 2013 with significant progress towards Abstral commercial launch in the fourth quarter. NeuVax (nelipepimut-S) Phase 3 PR
Galena Biopharma Reports Second Quarter 2013 Financial Results Lake Oswego, Oregon, August 8, 2013- Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company commercializing and developing innovative, targeted oncology treatments that address major unmet medical needs to adva
Read more →SLSGalena Biopharma Reports First Quarter 2013 Financial Results Lead product, NeuVax (nelipepimut-S), reached global site enrollment milestone for Phase 3 PRESENT trial; and commenced enrolling a Phase 2b in combination wi
Galena Biopharma Reports First Quarter 2013 Financial Results Lake Oswego, Oregon, May 9, 2013 Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today r
Read more →SLSWilliam L. Ashton Joins Galena Biopharma s Board of Directors Lake Oswego, Oregon
William L. Ashton Joins Galena Biopharma s Board of Directors Lake Oswego, Oregon, May 1, 2013 Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today a
Read more →SLSGalena Biopharma Acquires Abstral (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain Abstral was approved in the U.S. in 2011 and is the first and only fentanyl
Galena Biopharma Acquires Abstral (fentanyl) Sublingual Tablets in U.S., a Novel, Best-in-Class Treatment Approved for Breakthrough Cancer Pain Lake Oswego, Oregon, March 18, 2013 Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing innovative, targete
Read more →SLSGalena Biopharma Reports Year-End 2012 Financial Results Operating loss from continuing operations for the year ended
Galena Biopharma Reports Year-End 2012 Financial Results Lake Oswego, Oregon, March 12, 2013 Galena Biopharma (NASDAQ: GALE), a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today rep
Read more →SLSGalena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants Lake Oswego, Oregon
Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants Lake Oswego, Oregon, December 18, 2012 Galena Biopharma (NASDAQ: GALE) announced today the pricing of an underwritten public offering of 15,156,250 units at a public offering price of $1.60 per u
Read more →SLSGalena Biopharma Announces Public Offering of Common Stock and Warrants Lake Oswego, Oregon
Galena Biopharma Announces Public Offering of Common Stock and Warrants Lake Oswego, Oregon, December 17, 2012 Galena Biopharma (NASDAQ: GALE) announced today that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwri
Read more →SLSGALENA BIOPHARMA ANNOUNCES SIGNATURE OF COMMERCIALIZATION PARTNERSHIP WITH TEVA FOR ISRAEL Partnership includes future commercialization of NeuVax in Israel and financial support Key clinical sites approved and establish
GALENA BIOPHARMA ANNOUNCES SIGNATURE OF COMMERCIALIZATION PARTNERSHIP WITH TEVA FOR ISRAEL Partnership includes future commercialization of NeuVax in Israel and financial support Key clinical sites approved and established in Israel for PRESENT Phase 3 trial Lake Oswego, Oreg
Read more →SLSGalena Biopharma Reports Third Quarter 2012 Financial Results Lake Oswego, Oregon
Galena Biopharma Reports Third Quarter 2012 Financial Results Lake Oswego, Oregon, November 13, 2012 Galena Biopharma, Inc. (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance can
Read more →SLSGalena Biopharma Reports Second Quarter 2012 Financial Results Lake Oswego, Oregon
Galena Biopharma Reports Second Quarter 2012 Financial Results Lake Oswego, Oregon, August 14, 2012 Galena Biopharma, Inc. (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance canc
Read more →SLSGalena Biopharma Reports First Quarter 2012 Financial Results Lake Oswego, Oregon
Galena Biopharma Reports First Quarter 2012 Financial Results Lake Oswego, Oregon, May 14, 2012 Galena Biopharma (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, t
Read more →SLSGalena Biopharma Announces Exercise of Underwriters Over-Allotment Option and Closing of $14.5 Million Public Offering of Common Stock Lake Oswego, Oregon
Galena Biopharma Announces Exercise of Underwriters Over-Allotment Option and Closing of $14.5 Million Public Offering of Common Stock Lake Oswego, Oregon, April 16, 2012 Galena Biopharma (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncol
Read more →SLSGalena Biopharma Announces Public Offering of Common Stock Lake Oswego, Oregon
Galena Biopharma Announces Public Offering of Oswego, Oregon, April 4, 2012 Galena Biopharma (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet medical needs to advance cancer care, announced today that i
Read more →SLSGalena Biopharma Reports Fourth Quarter and 2011 Financial Results and Provides Business Update Lake Oswego, Oregon
Galena Biopharma Reports Fourth Quarter and 2011 Financial Results and Provides Business Update Lake Oswego, Oregon, March 28, 2012 Galena Biopharma (NASDAQ: GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet med
Read more →SLSSECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 20, 2012 GALENA BIOPHARMA, INC. (Exact name of registrant as specified in its charter)
Read more →SLSGALENA BIOPHARMA ENTERS INTO EXCHANGE AGREEMENTS WITH WARRANT HOLDERS Agreement Simplifies Company s Balance Sheet and Provides Future Financing Flexibility Lake Oswego, Oregon
GALENA BIOPHARMA ENTERS INTO EXCHANGE AGREEMENTS WITH WARRANT HOLDERS Agreement Simplifies Company s Balance Sheet and Provides Future Financing Flexibility Oswego, Oregon, December 6, 2011 Galena Biopharma (NASDAQ: GALE), a biotechnology company focused on developing innova
Read more →SLSGalena Biopharma Reports Third Quarter 2011 Financial Results and Provides Business Update NeuVax (E75) makes significant progress towards initiating the Phase 3 PRESENT ( P revention of R ecurrence in E arly- S tage, No
Galena Biopharma Reports Third Quarter 2011 Financial Results and Provides Business Update NeuVax (E75) makes significant progress towards initiating the Phase 3 PRESENT ( P revention of R ecurrence in E arly- S tage, Node-Positive Breast Cancer with Low to Intermediate HER2
Read more →SLSRXi Pharmaceuticals to Strengthen Strategic Focus by Separating into Two Publicly Traded Companies Galena Biopharma to Focus on Targeted Cancer Therapies RXi Pharmaceuticals to Focus on RNAi-Based Therapeutics Separation
RXi Pharmaceuticals to Strengthen Strategic Focus by Separating into Two Publicly Traded Companies Galena Biopharma to Focus on Targeted Cancer Therapies RXi Pharmaceuticals to Focus on RNAi-Based Therapeutics Separation of oncology and RNAi programs expected to enhance sh
Read more →SLSRXi Pharmaceuticals Licenses Novel, Targeted Cancer Vaccine for Gynecological Cancers Vaccine targets Folate Binding Protein (FBP) which is over-expressed in more than 90% of ovarian cancers and in the majority of other
RXi Pharmaceuticals Licenses Novel, Targeted Cancer Vaccine for Gynecological Cancers Vaccine targets Folate Binding Protein (FBP) which is over-expressed in more than 90% of ovarian cancers and in the majority of other adenocarconimas. RXi plans to initiate Phase 1 clinica
Read more →SLSRXi Pharmaceuticals Provides Update and Reports Financial Results for Q2 2011 NeuVax (E75) makes significant progress towards initiating the Phase 3 PRESENT ( P revention of R ecurrence in E arly- S tage, Node-Positive B
RXi Pharmaceuticals Provides Update and Reports Financial Results for Q2 2011 WORCESTER, Mass., August 15, 2011 RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major
Read more →SLSRXi Pharmaceuticals Strengthens NeuVax TM (E75) Patent Portfolio RXi acquires patent rights covering use of NeuVax in combination with trastuzumab (Herceptin ; Genentech/Roche); and use in low-to-intermediate HER2 breast
RXi Pharmaceuticals Strengthens NeuVax TM (E75) Patent Portfolio RXi acquires patent rights covering use of NeuVax in combination with trastuzumab (Herceptin ; Genentech/Roche); and use in low-to-intermediate HER2 breast cancer patients not eligible for Herceptin therapy.
Read more →SLSRXi Pharmaceuticals Reports Financial Results for the First Quarter of 2011 Acquisition and financing completed to enable clinical development of lead product candidates. NeuVax is slated to commence Phase III clinical t
RXi Pharmaceuticals Reports Financial Results for the First Quarter of 2011 Acquisition and financing completed to enable clinical development of lead product candidates. NeuVax is slated to commence Phase III clinical trials under a Special Protocol Assessment (SPA) in 1H
Read more →SLSRXi Pharmaceuticals Announces Public Offering of Common Stock and Warrants
RXi Pharmaceuticals Announces Public Offering of Common Stock and Warrants WORCESTER, Mass., April 14, 2011 (BUSINESS WIRE) RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addre
Read more →Competitive Position
How SLS ranks across every disease it competes inCompetitive Position is a premium feature
See how SLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial